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Abstract
Introduction: Multimorbidity, the presence of two or more chronic diseases in an individual, is a
pressing medical condition. Novel prevention methods are required to reduce the incidence of
multimorbidity. Prognostic predictive models estimate a patient’s risk of developing chronic
disease. This thesis developed a single predictive model for three diseases associated with
multimorbidity: diabetes, hypertension, and osteoarthritis.
Methods: Univariate logistic regression models were constructed, followed by an analysis of the
dependence that existed using copulas. All analyses were based on data from the Canadian
Primary Care Sentinel Surveillance Network.
Results: All univariate models were highly predictive, as demonstrated by their discrimination
and calibration. Copula models revealed the dependence between each disease pair.
Discussion: By estimating the risk of multiple chronic diseases, prognostic predictive models
may enable the prevention of chronic disease through identification of high-risk individuals or
delivery of individualized risk assessments to inform patient and health care provider decisionmaking.
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Chapter 1

1

Introduction

Prognostic predictive models (PPM) estimate a patient’s risk for future disease development
based on the patient’s current predictors of disease (1,2). Potential predictors, including patient
demographics, family history, lifestyle factors, medical conditions, or genetic factors (3), are
used to produce risk estimates of disease. These estimates can be used by primary care
practitioners (PCP) in their primary prevention activities with patients (4,5). Many chronic
diseases have been accurately predicted through risk estimation using prognostic predictive
models (6–8), such as cardiovascular disease (7,9). These tools have been shown to improve
patients’ risk perception and knowledge (10), as well as to modify PCP care, including
prescribing behaviours (11). The objective of a PPM is to inform patient and PCP decisionmaking by providing risk estimations and identifying high-risk individuals to target with riskreducing interventions, thereby reducing the future incidence of disease.
The occurrence of two or more chronic diseases within a single patient, or multimorbidity, is a
growing concern in the health care community. Prevalence estimates vary due to inconsistent
definitions of multimorbidity; levels in Canadian older adults range from 55 to 98% (12).
Methods of preventing the development of multimorbidity are severely lacking (13); novel
methods of prevention must be developed to reduce future incidence. One potential method that
may aid in preventing future cases of multimorbidity is the use of prognostic predictive models
aimed at informing patients and their care providers about multimorbidity risk.
A prognostic predictive model capable of estimating the risk of multiple diseases simultaneously
would deliver a comprehensive risk assessment that could be used to identify patients at highest
risk of disease in general. This model would incorporate aspects beyond risk factors for
individual diseases when estimating risk; for example, prior morbidities would be included as
predictors. Risk estimates produced by this model would include more than an overall risk of
disease; it would present a comprehensive description of patient risk for multiple outcomes,
including high-risk individual diseases, common disease pairings, and/or common clusters of
chronic disease. In the past, the development of models capable of estimating risk of multiple
1

diseases has been restricted by the lack of datasets large enough and rich enough to support the
production of such estimates. Recently established large-scale electronic medical record (EMR)
databases (14–17) represent a potential source of data of the size necessary to support efforts in
multimorbidity risk modelling.
Primary prevention is one of the fundamental goals of primary care (18), making primary care an
ideal setting to deploy such methods to reduce multimorbidity risk. Modelling risk of multiple
diseases could impact clinical practice twofold. First, it would identify patients at highest risk,
allowing the PCP to target these patients with risk-reducing interventions (19). Second,
practitioners and patients are often tasked with determining which risk factors are of the greatest
importance, as these should be targeted first. Risk modelling of multiple diseases would identify
risk factors that significantly contribute to the risk of multiple diseases to maximize the impact of
risk factor modification and reduce intervention-burden on patients. It is hoped that these
targeted interventions will help prevent future incidence of multimorbidity.
Traditionally, risk is modelled for individual diseases under the assumption that disease develops
independent of other diseases; however, we know from the study of multimorbidity that this
assumption is often false. Occurrence of diseases in the same individual is not an independent
event; disease processes influence the development or progression of other diseases leading to
chronic diseases often occurring together (20–22). For this reason, the estimation of disease risk
under the assumption that disease occurrences are independent events does not accurately reflect
a patient’s true risk of disease. Therefore, an understanding of the dependence that exists
between each disease is required prior to the construction of a prognostic predictive model for
multiple chronic diseases. Given this, models can be built to describe the dependence between
multiple diseases and estimate their risk of occurring in the same individual. The two main goals
of this work are 1) to build a prognostic predictive model that both accounts for existing chronic
disease and predicts the occurrence of multiple diseases simultaneously and 2) to examine the
dependence that exists between three chronic diseases – diabetes, hypertension, and osteoarthritis
– after adjusting for known risk factors. To achieve this, two objectives were identified: 1) to
construct a univariate multivariable logistic regression model for each chronic disease, which
allowed for 2) the construction of a copula that captures their joint dependence after adjusting for
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risk factors. The resulting model achieves both goals, since it can be used to make risk
predictions and it can be used to assess dependence in disease development.
This thesis first explores chronic disease, namely multimorbidity, and the possibility of
predicting multiple diseases using prognostic predictive models. Electronic medical records are
discussed as a potential data source. Subsequently, the methods of developing such a model are
presented, followed by the resulting model. Finally, the model that was developed for this thesis
is compared to existing research into prognostic predictive models and multiple diseases. In
addition, the limitations and implications of the model produced for this thesis are discussed.
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Chapter 2

2

Literature Review

The following literature review first describes chronic disease, particularly multimorbidity, and
its impacts. It continues by presenting prognostic predictive models as a potential method of
supporting the primary prevention of chronic disease and multimorbidity. It then finishes by
describing two requirements of multiple disease risk estimation: advanced statistical
methodologies and electronic medical record data.

2.1

Chronic Disease

As the leading cause of death worldwide, chronic disease represents one of the world’s largest
challenges (23). Disease is categorized into two distinct types: chronic and acute. Acute diseases
are characterized by their short duration. Patients typically recover from their disease within a
brief period of time (24); the length of this period is dependent upon the disease context. Acute
diseases are most often communicable, or transmitted from person to person, and thus commonly
referred to as “communicable diseases”. On the other hand, chronic diseases are long-lasting in
duration. Patients recover from their disease only after an extended period of time, if ever; many
chronic diseases are lifelong diseases. Chronic diseases are most commonly non-communicable,
or not transmitted from person to person. There are some exceptions to this, most notably
HIV/AIDS (25). In the past, acute infectious diseases were the main cause of morbidity and
mortality, globally. Typhoid, cholera, smallpox, tuberculosis, and diphtheria, among other
infectious and parasitic diseases were common until the early twentieth century (25). Due to
recent advancements in health care and the ability to treat (and often cure) infectious diseases,
such as the advent of antibiotics and vaccines and improvements in housing, sanitation, water
supply, and nutrition, rates of infectious diseases have severely fallen. However, due to the
increased lifespan resulting from the factors mentioned, there has been a concurrent rise in the
occurrence of chronic diseases. Chronic diseases such as cardiovascular disease, cancer, and
COPD are among the leading causes of death for developed nations (25). One of the main
focuses of today’s health care efforts is the treatment and prevention of chronic diseases.

4

2.1.1

Definition

There is no single, agreed upon definition of chronic disease (26). Most definitions depend on
either disease duration or disease transmission; however, these definitions will produce
inconsistent classifications of disease. As described above, HIV is a communicable disease for
which no cure exists that results in lifelong health effects. Many organizations have constructed
definitions of chronic disease and lists of diseases they consider chronic diseases. These
definitions are often non-specific; for example, the U.S. National Center for Health Statistics
defines chronic disease as “a disease lasting 3 months or longer” (27). Additionally, these
definitions often disagree. The Public Health Agency of Canada considers five main groups of
chronic diseases: cardiovascular diseases, cancers, chronic respiratory diseases, diabetes, and
mood and anxiety disorders (28). By the U.S. National Center for Health Statistics definition,
diseases such as epilepsy or chronic kidney disease would be considered chronic diseases,
whereas by the Public Health Agency of Canada definition they would not.
Given this lack of a standard definition of chronic disease, it is not possible to use it as an
outcome for prediction without significant additional effort. However, this thesis was not subject
to this issue as it simply selected three diseases for prediction that are managed in primary care
and possess lifelong clinical implications. The methodology in the thesis is general and can be
applied to any outcome of interest.

2.1.2

Prevalence

In Canada, greater than one fifth of Canadians age twenty or older live with at least one major
chronic disease (CVD, cancer, chronic respiratory disease, and diabetes) (29). In Canadians aged
65 or older, this proportion of individuals living with at least one major chronic disease grows to
over 40% (29).

2.1.3

Risk Factors

A risk factor is some characteristic that is causally associated with a given disease; these can be
environmental, genetic, behavioural, somatic, or social. Risk factors are distinct from risk
markers, which are associated with risk of disease non-causally or of unproven causation (30).
Risk factors must be proven to be causally associated with risk of disease through the use of
5

epidemiologic methods. For example, smoking has been shown to impart an increased risk for
lung cancer (31), making it a risk factor. Identification of risk factors is important for two
reasons; it allows for 1) risk assessments in which an individual’s risk factors are assessed to
enable risk estimation and 2) subsequent intervention upon modifiable risk factors. Most diseases
are multifactorial (i.e., their development is influenced by multiple risk factors). Indeed, it is
common for individuals to have more than one risk factor. When an individual possesses
multiple risk factors, these risk factors can have an additive or multiplicative impact on risk; this
effect is known as interaction. When risk factors interact in an additive manner, the individual’s
total risk is greater or less than the sum of the component risks (32). When risk factors interact in
a multiplicative manner, the individual’s total risk is greater or less than the product of the
component risks (32). Risk factors are often targeted with interventions aimed at reducing a
person’s risk of developing chronic disease.
Risk factors can be modifiable or non-modifiable. Modifiable risk factors can be changed
through some intervention. Interventions often include behavioural or lifestyle changes, medical
procedures, or pharmaceutical treatments. For example, smoking is a risk factor for
cardiovascular disease, which can be modified by quitting smoking; studies have demonstrated
that quitting smoking reduces the risk of developing cardiovascular disease (33,34). Nonmodifiable risk factors cannot be changed. For example, family history is non-modifiable risk
factor for cardiovascular disease. Intervention upon risk factors is the focus of primary
prevention efforts, which aim to lower an individual’s risk of developing disease.
Many chronic diseases share common risk factors. For example, obesity is a known risk factor
for diabetes (35,36), depression (37), and osteoarthritis (38–40). Where shared risk factors exist
(and are modifiable), targeting these first will have the largest impact on an individual’s risk of
disease overall. In patients at high risk of multiple diseases, it is preferable to target risk factors
associated with multiple diseases; in this situation, the individual would be subject to fewer
interventions than if each disease were intervened upon individually, thus reducing intervention
burden on the patient.

6

2.1.4

Multimorbidity

Multimorbidity is an extremely common medical condition, especially among older adults (12).
Although definitions vary, multimorbidity is commonly considered the presence of two or more
chronic conditions within an individual (41). For example, a patient diagnosed with both asthma
and diabetes has multimorbidity. Multimorbidity can be contrasted with comorbidity. Both of
these terms refer to multiple chronic diseases within the same individual; however, when
examining comorbidities, there is always an index disease that is the primary focus, for which its
care is modified when additional morbidities are considered. Multimorbidity, on the other hand,
does not prioritize one disease over another.
Despite professional agreement that multimorbidity is a pressing health issue (12), there is no
standard, consistently used definition of multimorbidity (42–44). The European General Practice
Research Network defines multimorbidity as “any combination of chronic disease with at least
one other disease (acute or chronic) or bio-psychosocial factor (associated or not) or somatic risk
factor” (45), without a list of diseases or conditions that should be considered. In contrast, the
Public Health Agency of Canada considers multimorbidity to be two or more of the following
diseases within the same individual: heart disease, stroke, cancer, asthma, COPD, DM, arthritis,
Alzheimer’s or other dementia, mood disorder (depression), and anxiety (29). A recent
systematic review by Fortin et al. examined the impact of including various numbers of diseases
in a definition for multimorbidity on the prevalence of multimorbidity (42). Findings of this
systematic review demonstrated that inclusion of at least 12 chronic conditions in the definition
of multimorbidity resulted in stable prevalence estimates; including more conditions in the
definition did not significantly alter the prevalence estimates. Fortin et al. suggest including the
12 most prevalent chronic conditions in a definition of multimorbidity.
Prevalence estimates in the literature are inconsistent due to varying definitions of
multimorbidity; however, estimates of multimorbidity prevalence in older adults range from 55
to 98% (12). According to the Public Health Agency of Canada definition of multimorbidity, the
prevalence of multimorbidity in 2014 was 14.8% in Canadians aged 20 and older.
Multimorbidity has impacts on both patients and their HCPs. This complex condition that
imposes a huge burden on patients has been shown to reduce health-related quality of life, limit
7

activities of daily living, and decrease self-rated health (46,47). An inverse relationship has been
found between multimorbidity and health-related quality of life; as the number of multimorbid
diseases increases, health-related quality of life has been found to decrease (48). Issues such as
polypharmacy, fragmentation of care, and conflicting or competing health care recommendations
may be faced by patients with multimorbidity (12), making treatment of these individuals
complicated. The economic burden of multimorbidity is massive; in 2009, nearly 80% of health
care costs in Canada were due to individuals with multimorbidity (49). Wikström et al (50)
examined risk factors specifically for multimorbidity. They found that smoking, physical
activity, and BMI were significant contributors to risk of multimorbidity development.
Additionally, systolic blood pressure and low education contributed to risk of multimorbidity
among men. Dhalwani et al (51) examined the impact of physical activity on development of
multimorbidity among an older English population; they found a dose-response relationship
between levels of physical activity and multimorbidity: for those at higher levels of physical
activity, fewer developed multimorbidity. Dankel et al. (19) examined the impact of musclestrengthening activities on multimorbidity risk. Those who participated in the musclestrengthening activities had 26% lower odds of developing multimorbidity. These studies
demonstrate the importance of physical activity for the prevention of multimorbidity. Recently,
there has been a focus on developing strategies to prevent multimorbidity as health policy
makers and health care providers recognize the importance of multimorbidity (52). In 2015, the
Public Health Agency of Canada published a report that stressed the importance of addressing
chronic disease from a comprehensive, holistic approach, including consideration of
multimorbidity, rather than a single-disease-centred approach (53).
Three chronic diseases commonly associated with multimorbidity are diabetes mellitus,
hypertension, and osteoarthritis.

2.1.5

Diabetes Mellitus

Diabetes mellitus (DM) is a group of metabolic disorders characterized by elevated blood
glucose levels over prolonged periods (54). DM comprises two main conditions: type 1 DM, in
which the pancreas is not able to produce enough insulin and type 2 DM, in which the pancreas
produces insulin but the body’s cells fail to respond properly. As type 2 DM progresses, failure
to produce insulin may also develop (55). Type 1 DM, traditionally termed juvenile diabetes as
8

its onset typically occurs before adulthood, comprises approximately 10% of cases of DM (56).
The most common cause of type 1 DM is an autoimmune attack on the insulin-producing beta
cells of the pancreatic islets, resulting in insulin deficiency (57). Type 2 DM is the more common
of the two, comprising approximately 90% of cases of DM (56). Its onset is typically in
adulthood; however, a growing proportion of younger individuals are developing type 2 DM
(58). This is likely due to the increase in risk factors for DM, such as obesity, lack of physical
activity, and poor diet, in youth.
Based on national survey data, the population prevalence of DM (both type 1 and type 2) is
roughly 9.8% (29). Based on a Canadian study using electronic medical record data conducted
by Greiver et al., the prevalence within primary care patients was 8.2% (59). When corrected
using a corrected yearly contact group denominator, the population prevalence of DM was 7.6%
(59).
Patients with type 1 DM must manage their glucose levels using insulin injections; this requires
monitoring of blood glucose levels using repeated blood tests and administration of insulin
injections (60). Patients with type 2 DM do not always require insulin. Lifestyle changes, such as
proper diet and exercise, and medications (e.g., metformin), are used to manage patients with
type 2 DM (60). Insulin injections may be added to treatment when the disease has progressed;
however, most individuals do not initially require insulin (55).
Complications of DM are the same for both type 1 and type 2 DM and are minimized through
proper control of glucose levels (61,62). DM leads to both microangiopathy and
macroangiopathy, often resulting in severe complications, both acute and chronic (54). Acute
complications, such as hypoglycemia, hyperglycemia, and, less commonly, diabetic coma, can
occur within patients with DM. Chronic complications include diabetic nephropathy (i.e.,
damage to the kidney that can lead to chronic kidney failure); diabetic retinopathy (i.e., growth
of poor-quality blood vessels and swelling that can result in vision loss or blindness); diabetic
cardiomyopathy (i.e., damage to the heart muscle that can lead to heart failure); cardiovascular
disease; and foot ulcers.
Type 1 DM is currently not preventable (60); however, type 2 DM may be delayed or prevented
through the modification of risk factors (60). Non-modifiable risk factors for type 2 DM include
9

older age (36,63); male sex (36); polycystic ovarian syndrome (PCOS) (64); psychiatric
disorders such as schizophrenia (65,66), depression (67), bipolar disorder (66,68); family history
of type 2 diabetes (36); air pollution (69); and low socioeconomic status (70). Modifiable risk
factors for type 2 diabetes include obesity (35,36,63,70), waist circumference, lipid disorders
(36), hypertension (36,63), smoking (36,63), stress (36), and low physical activity (70). The
effectiveness of diet-and-exercise programs in reducing diabetes incidence through weight
reduction and regular physical activity has been demonstrated in many randomized controlled
trials (RCTs) (71–73). Bariatric surgery to facilitate weight loss has shown promise in preventing
type 2 DM development (74). Several pharmacotherapies have been investigated for type 2 DM
prevention. Metformin has been shown to significantly reduce risk of developing diabetes (71),
even after medication discontinuation (75,76). Other medications have been investigated,
including thiazolidinediones such as troglitazone (77), rosiglitazone (78), ramipril (79), and
pioglitazone (80); alpha-glucosidase inhibitors (81); orlistat (82); and incretin-based therapies
such as liraglutide (83); however, results remain indefinitive, limiting their use. Clinical practice
guidelines published by Diabetes Canada (formerly the Canadian Diabetes Association) (84)
recommend reduction of type 2 DM risk through a structured lifestyle modification program,
including weight loss, physical activity and pharmacological therapy with metformin or
acarbose, in patients with impaired glucose tolerance.

2.1.6

Hypertension

Hypertension is a condition in which blood pressure in the arteries is consistently elevated (85).
Hypertension due to some identifiable cause, such as pregnancy, polycystic kidney disease, or
medication, is referred to as “secondary hypertension”; this form of hypertension comprises only
5-10% of cases (86). Hypertension due to unknown causes is referred to as primary (or essential)
hypertension, constituting the remaining 90-95% of cases (86,87). Hypertension does not usually
cause symptoms; however, chronic high blood pressure is a known risk factor for cardiovascular
disease, stroke, vision loss, and chronic kidney disease (85,88). Reduction of blood pressure
through lifestyle modifications and medications reduces risk of complications (85,88). Patients
diagnosed with hypertension are encouraged to reduce their blood pressure to target blood
pressure recommended by various expert groups (89); the Canadian Hypertension Education
Program (90) recommends a target blood pressure of less than 140/90 for the general population.
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Based on the Canadian Health Measures Survey (CHMS), the national prevalence of
hypertension in Canada was 22.6% in the years 2012-2013 (91). Based on a Canadian study
using electronic medical record data conducted by Godwin et al., 22.8% of a primary care
population had a diagnosis of hypertension as of 2012 (92). Of this primary care population,
most patients (80%) diagnosed with hypertension were able to reach target blood pressure levels.
As hypertension does not result in symptoms (85), the burden of the disease itself on patients is
low. However, hypertension has a large impact on individuals when considering its long-term
complications; CVD, stroke, vision loss, and chronic kidney disease all have severe impacts on
an individual’s well-being.
Non-modifiable risk factors for hypertension include older age (93), diabetes (93,94), kidney
disease (95), and sleep apnea (96). Modifiable risk factors include obesity (93,94), smoking (93),
stress (97), tricyclic antidepressant use (98), and high salt intake (93,99).
Primary prevention of hypertension focuses on modification of its risk factors. For example, the
DASH diet (Dietary approaches to stop hypertension) (100) aims to reduce salt consumption
through modification of diet. Physical activity is commonly recommended to reduce risk of
hypertension; many epidemiologic studies have demonstrated a consistent dose-response
relationship between physical activity and development of hypertension, in which higher levels
of physical activity were associated with lower rates of hypertension (101). Additionally, weight
loss, even modest, has been shown to decrease risk of hypertension (102). Indeed, the Canadian
Hypertension Education Program recommends the following (103) for the prevention of
hypertension: regular physical activity; maintenance of a healthy body weight; alcohol
consumption within the Canadian low-risk drinking guidelines (104); maintenance of the DASH
diet (100); reduction of sodium consumption; and stress management.

2.1.7

Osteoarthritis

Osteoarthritis is a degenerative joint disease characterized by the breakdown of joint cartilage
and the underlying bone (105). Symptoms of osteoarthritis most commonly include joint pain
and stiffness (105). As the disease progresses, the severity of pain and stiffness increases, and
movement patterns are typically affected. The most commonly affected joints are those of the
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hands, neck, lower back, hips, and knees. Typical treatment of osteoarthritis involves lifestyle
modification and medications (106–108). Weight loss has been shown to reduce pain and
stiffness and improve function of the joint (109). Medications, such as non-steroidal antiinflammatory drugs, are used for treatment of pain. In cases where the impact of osteoarthritis
symptoms are severe and conservative forms of treatment are ineffective, joint replacement
surgery may be recommended, in which the affected joint is replaced with an artificial joint.
Replacement of hip and knee joints have been shown to be clinically (110,111) and cost effective
(112,113).
The population-based prevalence of osteoarthritis was estimated to be 13.0% in Canadians aged
20 and older (28). Based on a study in Canada using electronic medical record data conducted by
Birtwhistle et al., the prevalence of osteoarthritis within the primary care population was 14.2%
in 2012 (114).
The impact of osteoarthritis on individuals living with the disease is dependent upon the joint(s)
affected and the progression of disease. Osteoarthritis of the knee and hip can limit activities
such as running or walking, whereas osteoarthritis of the hand joints can impede activities such
as writing or typing. Degree of disease progression and an individual’s ability to manage
symptoms affects how activities are affected.
Efforts surrounding osteoarthritis management typically focus on treatment of symptoms, rather
than disease prevention. This is likely due to its slow, progressive nature with no clear point of
disease onset. Non-modifiable risk factors for osteoarthritis include leg length inequality (115),
older age (39,40,116–118), female sex (39,40,116,117), family history of osteoarthritis (116),
and osteoporosis (39). The modifiable risk factors for osteoarthritis are obesity (38–40,116–119),
previous joint injury (38,40,117,119), and physically intensive occupations (116). Suggested
osteoarthritis prevention efforts concentrate on obesity. For example, a diet-and-exercise
program aimed at weight reduction was found to be suggestive of a reduction in the incidence of
knee osteoarthritis (120). There is growing interest in preventing osteoarthritis through the
implementation of joint injury prevention programs (121). To date, there are no established
guidelines pertaining to the prevention of osteoarthritis.
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2.2
2.2.1

Prognostic Predictive Models
Overview

Prognostic predictive models can be used to estimate the risk of developing a chronic disease. In
particular, the objective of prognostic predictive models (PPMs) is to inform patients and care
providers about patient risk, and thereby motivate the use of interventions that prevent future
disease development. There are several levels of disease prevention, each used at different stages
of disease progression. Primary prevention describes the efforts taken prior to disease
development to reduce risk of future disease development (122,123). Common primary
prevention interventions include eating a healthy diet, quitting smoking, or exercising regularly.
Secondary prevention describes diagnostic efforts after disease onset but prior to clinical
manifestations (symptoms) of disease to detect the initial stages of disease, allowing for early
treatment; for example, breast cancer screening is done to detect the disease earlier, when
treatments are more effective (122,124). Tertiary prevention describes the actions taken to reduce
the impact and ease the burden of an on-going disease (122,125). One example of a tertiary
prevention intervention is physiotherapy following a joint injury to improve joint function. PPMs
are one tool used to support the primary prevention of disease.
Traditional primary prevention interventions include risk management. Risk management refers
to the forecasting and evaluation of patient risk and practices aimed at reducing this risk (126–
128). Individual risk factor management is a specific type of risk management. According to this
strategy, risk factors for chronic disease are individually assessed through risk assessments and
subsequently intervened upon; however, recent research has demonstrated that risk assessments
that examine a patient’s global risk of disease by considering multiple risk factors
simultaneously have been more effective in risk reduction (129). A patient’s global risk takes
into account the impact of multiple risk factors to estimate the risk that the patient will develop
disease within a given time period (130). One method of estimating a patient’s global risk of
disease is through the use of PPMs.
Previous methods of risk estimation have relied upon anecdotal evidence and professional
opinion of the practitioner and often vary between practitioners. PPMs represent an objective,
evidence-based method of assessing an individual's risk of future disease development using
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multiple risk factors (131). These models present estimated risk in the form of a risk score,
usually a numeric value where a greater value denotes greater risk (132). Alternatively,
individuals are assigned to categories corresponding to varying degrees of risk. Common PPMs
include the Framingham Risk Score for cardiovascular disease (9) and EuroScore to estimate risk
of death after a heart operation (133).
Multivariable statistical methods are used in PPMs. A PPM estimates the risk of some outcome
(future development of disease) based on a set of covariates (characteristics shown to indicate
risk, or risk indicators). This is distinct from past risk estimation methods where individual risk
factors were assessed independently then intervened upon. Compared to the use of a single
predictor, the use of multiple predictors allows for more accurate estimation of a patient’s risk
(5), as multiple risk factors commonly coexist within an individual (130). Interaction between
risk factors occurs when the joint effect on risk is greater than what would be expected by adding
or multiplying the effects of each risk factor; these interactions can be modelled by PPMs by
including an interaction term in the model (134). Characteristics of the patient, provider, or
practice can be included as covariates in the model. Potential patient level covariates include
patient demographics, family history, lifestyle factors, medical conditions, and genetic factors
(3). Potential provider level covariates include specialization (if any), years in practice, and
additional certifications. Potential practice level covariates include rurality, number of
practitioners, and geographic location. Inclusion of characteristics from multiple levels requires
the use of advanced methods such as multilevel modelling (135).
PPMs are distinct from etiologic research. The focus of prognostic research is to predict some
outcome, whereas etiologic research aims to identify the cause of some outcome (136). Both
prognostic and etiologic research use multivariable approaches; however, in etiologic research,
the goal is to isolate the main causal effect of some exposure by adjusting for the effects of other
confounding factors (136). In contrast, prognostic research uses a multivariable approach to
estimate risk of an outcome as accurately as possible by including as much potentially predictive
information as possible (5). As such, covariates included in a prognostic model do not have to be
causally related to the outcome (and are often not). Risk management practices can then be used
to minimize the risk among high-risk patients by intervening on factors that are known to be
causal.
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2.2.2

Conceptual Model

Two theories exist that drive the use of PPMs, one at the individual level and another at the
population level. At the individual level, the theory driving the use of PPMs posits that
knowledge of disease course enables patients and practitioners to make informed decisions to
avoid or deter the development of disease (5). At the population level, the use of PPMs is driven
by the need for identification of patients at high-risk of disease, enabling targeted interventions
aimed at reducing risk within these patients (5). The following conceptual model describes the
process of risk estimation via PPMs, from both the individual and population perspectives.

Figure 1: Conceptual Model for Risk Assessment
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The four stages of risk assessment outlined in the conceptual model above will be discussed
below.

2.2.2.1

Stage 1: Use of Prognostic Predictive Models

Risk assessments, which commonly include a PPM, can occur in two ways. In the first, either the
patient or PCP is concerned about risk of future morbidity and the PCP actively performs a risk
assessment. In this case, there must be some initiation or interest in risk assessment by either the
patient or PCP. Alternatively, risk assessments can run passively in the background, assessing all
patients’ risks, and send an alert when a patient is classified as high-risk. In this case, the risk
estimation model is run regardless of patient or PCP concern about future morbidity. Integration
of risk assessments into electronic medical record (EMR) systems facilitates both these
strategies, as tools within an EMR are easily accessible to the PCP and are able to run in the
background of the EMR. Building these tools into EMRs results in simple incorporation into
clinical workflow to offer real-time recommendations.

2.2.2.2

Stages 2 & 3: Change in Provider and Patient Behaviour

PPMs can be used in primary care to inform PCP decision making regarding risk reduction. Most
often PPMs are used as a part of a risk assessment. Studies examining the use and impact of
PPMs in primary care in Canada are rare; most PPM studies focus on the development or
validation of models, but do not evaluate how current models are used (137). However, many
Canadian guidelines advocate for the use of risk assessments. The Canadian Cardiovascular
Society recommends cardiovascular risk assessment using every 5 years for men and women
between ages 40 and 75 using PPMs such as the modified Framingham Risk Score or
Cardiovascular Life Expectancy Model (138). The results of these risk assessments are used to
inform decisions regarding interventions to reduce risk of cardiovascular events. Other examples
include the 2010 Clinical Practice Guidelines from Osteoporosis Canada, which recommends
osteoporosis and fracture risk assessment for individuals over age 50 who have experienced a
fragility fracture or who have a history of falls (139). These risk assessments can inform
interventions such as exercise and prevention of falls, calcium and vitamin D supplementation,
or pharmacologic therapy.
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Many factors limit the use of PPMs in clinical practice. A qualitative study examined barriers
cited by PCPs limiting their use of PPMs in clinical practice including lack of lifestyle
recommendations, legal and regulatory constraints, and lack of accuracy of risk scores (140).
PCPs felt that predictive models focused more on non-modifiable risk factors, such as age, thus
limiting their ability to give recommendations on more relevant, modifiable risk factors such as
lifestyle. PCPs also expressed concerns over the current regulations that did not place a focus on
disease prevention; no remuneration exists for time spent on risk assessment and prevention.
PCPs feared that the estimated risk scores were not an accurate representation of individual
patient’s risks, and thus were less likely to use the PPM.

2.2.2.3

Stage 4: Change in Patient Outcomes

Similar to studies looking at their use, few studies in Canada have examined the impact of PPMs
on clinical outcomes, such as impact on risk, disease incidence, or physician behaviours;
however, some studies exist examining their use. The National Health Service (NHS) Health
Check is a health check-up for adults that includes a CVD risk assessment (141). All adults in
England between the ages 40 and 74 without a pre-existing condition are invited by their PCP or
local authority for a free NHS Health Check every 5 years in an effort to reduce risk of chronic
disease. The introduction of the NHS Health Check was shown to be associated with significant
reductions in CVD risk, as well as improvements in statin prescriptions (142). The
Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes
Mellitus (RAMP-DM) in Hong Kong had similarly promising results, finding that a risk
assessment and management program (which included a risk assessment component) was
associated with fewer cardiovascular complications and lower all-cause mortality after 3 years
(143). In contrast, a systematic review conducted by Brindle et al. described several studies that
observed no impact from PPM risk assessment on the observed outcomes, which included
predicted risk of CVD, fatal or non-fatal CVD events, risk factor levels, prescription of riskreducing drugs, and changes in health-related behaviour (144); however, this review frequently
noted that the PPM’s use by PCPs was either poorly recorded or not recorded at all. Indeed, it is
unclear whether the lack of impact was due to the efficacy of the PPM or the lack of use by the
physician.
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2.2.3

Settings of Prognostic Predictive Model Use

Primary care is the first point of patient contact where, most often, patients are seen prior to
disease development; once patients reach secondary or tertiary levels of care they have already
developed disease, thus prognostic risk estimation is of little value in these clinical settings. For
this reason, primary care is an ideal setting for targeted primary prevention efforts, including the
use of PPMs. PPMs can be used to inform the PCP decision-making process surrounding risk
management, such as whether or not to recommend risk lowering interventions. Many guidelines
recommend the use PPMs to detect high-risk individuals for primary prevention efforts
(145,146). One common PPM used in primary care is the Framingham model for cardiovascular
disease (CVD) (147), which estimates a patient’s risk of developing CVD in the next 10 years
based on risk factors including age, sex, cholesterol levels, and smoking status. PCP decisions
such as whether or not to prescribe statins or to recommend lifestyle changes are informed by
this model.
Additionally, PPMs are commonly used as online tools to deliver risk estimates to the general
population over the internet (148,149). This method allows a larger population, beyond primary
care patients, to access personalized risk estimates in a convenient manner and receive
recommendations on ways to reduce risk. Online risk assessments are based on established PPMs
that have been empirically developed and validated; however, these models are sometimes
modified to substitute covariates that are not commonly known by individuals. For example,
personal blood cholesterol within the Framingham cardiovascular risk assessment may be
replaced with an average value as most individuals will not likely know their blood cholesterol
levels off-hand. Given the current status of PPM use in primary care, online risk assessments are
able to reach a much greater proportion of the population. The deployment of online PPMs aims
to reduce the overall incidence of disease within the community by informing individuals of their
personal risk and subsequently recommending risk reducing interventions.

2.2.4

Prognostic Predictive Model Development

The development of a PPM is a complex process involving risk factor identification, data
processing, and statistical analysis. For a complete description of the processes involved in PPM
development, see the Transparent Reporting of a Multivariable Prediction Model for Individual
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Prognosis or Diagnosis (TRIPOD) Statement (150). Ideally, there are three stages in prognostic
research: model development, validation, and clinical impact evaluation (5).
Model development requires knowledge of the relevant risk factors for the disease of interest; a
review of the relevant literature will reveal risk factors for the disease. Also required for model
development is a dataset from which to build the model. When developing a PPM, it is optimal
to use a prospective cohort study conducted specifically to collect data to inform the PPM
development (151). However, due to the high costs associated with primary data collection,
development of PPMs may make use of data previously collected (retrospective data). Results
from retrospective data are more prone to bias as predictor and outcome information is less
systematically recorded (1). Common sources of retrospective data include previous
observational studies, randomized controlled trials, and health administrative data (6,152,153).
PPMs are constructed using statistical techniques, commonly regression, to estimate risk of
disease development in the future (2). The type of regression used is primarily dependent on the
type of outcome that is to be predicted. For example, when continuous outcomes are to be
predicted, linear regression (154) is commonly used; when binary (“dichotomous” or yes/no)
outcomes are to be predicted, logistic regression (155) is commonly used; or when time-to-event
outcomes are to be predicted, Cox regression (156) is commonly used. Each of these methods
posit a (possibly transformed) linear relationship between the covariates and the outcome and are
each considered Generalized Linear Models. Advanced methods, such as Generalized Additive
Models (157), can be used to model more complex, non-linear relationships between covariates
and outcomes. These methods offer the advantage of accounting for non-linearity between the
covariates and the outcome, better modelling the relationships in the data; however, they
sacrifice some interpretability of the model, as such models are often more difficult to
understand. Disease status is generally considered a binary outcome; a patient either has the
disease or they do not. For this reason, logistic regression or survival analysis methods are most
commonly used to model disease outcome data for PPMs. Other non-regression methods exist to
predict future disease development; these include decision trees (158), where patients pass
through a series of yes/no questions to eventually classify their risk of disease development, or knearest neighbours (159), where a patient is classified according to the risk corresponding to
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those most similar to them. While these models are sometimes more easily interpreted, they are
not as frequently used as regression methods.
Following the development of the model, it must be validated to assess its accuracy. Model
validation consists of internal and external validation (160). Internal validation is performed on
data from the same source used to construct the model, either using a held-out portion of the data
or methods such as cross validation (161) or bootstrapping (162). External validation applies the
model to a different population that is similar to determine its accuracy (163). At a minimum,
validation looks at discrimination and calibration. Discrimination is the ability to correctly
assign higher risk to a patient who ultimately experiences the outcome compared to the patient
who does not (4). Discrimination is commonly assessed via the c-statistic or an ROC curve
(164). Calibration is a measure of how well a model fits the data (4); this describes how well the
risk estimates the true proportion of patients that will develop disease. For patients assigned a
given risk (probability), approximately the same proportion of patients should actually go on to
develop disease in a model with high calibration. This can be assessed using the HosmerLemeshow test (155) or a calibration plot; however, the Hosmer-Lemeshow test has been shown
to be over-sensitive when dealing with large datasets (3).
The final step in the development of a PPM is to assess its clinical impact (137). Rather than
simply assessing performance of the model (i.e. how well the model predicts the outcome), this
stage assesses the model’s impact on physician practices, patient care, and patient outcomes.
Examples of impacts include modification of physician behaviours, such as prescribing patterns;
modification of patient risk; and change in disease incidence. Most PPMs are internally validated
at a minimum; however, few are validated on an external dataset, and even fewer have had their
clinical impact assessed (165).

2.2.5

Prognostic Predictive Model for Multiple Diseases

Traditional PPMs estimate risk for individual diseases; however, many chronic diseases have
been found to cluster in the same individuals, whether they occurred at the same time or
accumulated over a period of time (20–22). As a result, patients are often burdened by multiple
diseases. PPMs for multiple diseases have been poorly studied in the literature. In order to enable
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the development of PPMs for multiple diseases, advanced statistical methodologies and data that
are numerous and highly descriptive, such as electronic medical record data, are required.

2.3

Methodologies for Multiple Disease Risk Estimation

To understand the methodologies required for the estimation of multiple disease risk, an
understanding of the concepts related to joint distributions and dependence are first required.
Subsequently, an overview of one method for the estimation of multiple disease risk is presented.

2.3.1

Joint and Marginal Distribution of Binary Random Variables

Consider two random variables 𝑋𝑑 and 𝑋ℎ , each of which can take the value 0 or 1. Let 𝑋𝑑 = 1
represent the event that an individual develops diabetes within a 5-year period and 𝑋𝑑 = 0
represent no development of diabetes within that interval. Let 𝑋ℎ be the analogous random
variable, but for hypertension.
After waiting for the 5-year period, the values (𝑥𝑑 , 𝑥ℎ ) are observed, which are the realizations
of the two random variables. There are four possibilities: (0,0) if the patient develops neither
disease; (0,1) if the patient develops hypertension but not diabetes; (1,0) if the patient develops
diabetes but not hypertension; and (1,1) if the patient develops both diseases. Note that these four
possibilities are mutually exclusive and exhaustive – the patient must fall into exactly one of
these categories.
By observing many patients, the probability of observing any one of these realizations may be
estimated. The four probabilities give the joint distribution of the two random variables. (Note,
however, that since they sum to one, if three probabilities are known we can compute the fourth.)
A marginal distribution refers to the distribution of one disease without consideration of the
other; each variable has a marginal distribution. In this example, one marginal distribution would
describe the probabilities of developing diabetes without considering hypertension while the
other would describe the probability of developing hypertension without considering diabetes.
These can be computed by marginalizing out the other variable – for example, the marginal
probability of developing diabetes would be the probability of observing (1,0) plus the
probability of observing (1,1).
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Suppose the development of diabetes and the development of hypertension were truly
independent of each other; that is, the occurrence of diabetes was not related to the occurrence of
hypertension. In this case, the joint distribution of diabetes and hypertension would be no
different from what would be expected by multiplying the marginal probabilities of diabetes and
hypertension. This is the null hypothesis commonly used when analyzing contingency tables
with the 𝜒 2 test or Fisher’s exact test.
The 𝜒 2 test evaluates the null hypothesis that each disease is independent of the other by
comparing the expected and observed disease frequencies (166). When sample sizes are small,
Fisher's exact test should be used (166).
The same methods can be applied to the analysis of three diseases. In this case, the frequencies
of each combination of the three diseases are considered. Again, the 𝜒 2 test and Fisher's exact
test can be used to evaluate the null hypothesis that each disease is independent of the others.
Dependence among the variables describing disease development may be observed in a
population because they have common risk factors. For example, higher BMI may be associated
with development of diabetes and development of hypertension. If a contingency table is
analyzed using a sufficiently large population with a range of BMIs, dependence will be detected
between 𝑋𝑑 and 𝑋ℎ . However, it may be that for any given value of BMI (or perhaps a small
range) the development of the two diseases happens independently. Assessment of dependence
after stratifying on a risk factor can be achieved by the Cochrane-Mantel-Haenszel test. The
Cochrane-Mantel-Haenszel test accounts for confounding variables through stratification into
discrete categories; however, this method does not directly make use of continuous variables.
Instead, a two-stage approach to model the joint distribution of disease development can be used.
This approach first uses univariate multivariable logistic regression to model the marginal
distribution of development of each disease and then uses a copula to combine the marginal
distributions together into a joint distribution. This approach has the ability to 1) account for
more than two diseases at a time; 2) adjust for both categorical and continuous variables; and 3)
ultimately be used in the construction of a predictive model.
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A copula is a multivariate probability distribution used to describe the non-linear dependence
between multiple outcomes where each univariate marginal distribution is uniquely defined
(167,168). Copulas are defined by Sklar’s theorem, which states that every multivariate
cumulative distribution function of the variables considered can be expressed in terms of their
univariate marginal distributions and a copula (169). The copula (meaning link in Latin) links the
univariate marginal distributions together, forming the multivariate joint distribution.

2.3.2

Univariate Multivariable Logistic Regression

The first step in constructing a copula is the estimation of univariate multivariable logistic
regression models. Univariate multivariable logistic regression seeks to understand the
relationship between multiple covariates and a single binary outcome (univariate: one outcome;
multivariable: multiple covariates) (155). Univariate logistic regression is based on the logistic
function, which is used for modelling the probability distribution of binary data as its output only
takes on values between zero and one due to its S-shape. The logistic function (t) is defined as
follows:
𝜎(𝑡) =

1
1 + 𝑒 −𝑡

The logistic function applied to a linear function of several explanatory covariates gives a
logistic regression function.
𝐹 (𝑥𝑖 ) =

1
1+ 𝑒 −(𝛽0 +𝛽𝑖 𝑥𝑖 )

= 𝜎(𝛽0 + 𝛽𝑖 𝑥𝑖 )

Where 𝛽0 denotes some constant, 𝛽𝑖 denotes some constant(s) by which the explanatory
variable(s) will be multiplied, and 𝑥𝑖 denotes the explanatory variable(s). Given knowledge of all
explanatory covariates and estimates 𝛽̂𝑖 of the coefficients, the probability of experiencing the
outcome is estimated by
𝐹̂ (𝑥𝑖 ) =

1
̂
̂
1+ 𝑒 −(𝛽0 +𝛽𝑖 𝑥𝑖 )

= 𝜎(𝛽̂0 + 𝛽̂𝑖 𝑥𝑖 ).

Odds can be estimated by applying the exponential function.
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̂

̂

Odds = 𝑒 𝛽0 +𝛽𝑖 𝑥𝑖
The logistic regression coefficients were estimated using maximum likelihood estimation.

2.3.3

Copulas

Once univariate multivariable logistic regression models have been constructed, the copula is
then constructed, which ties together the univariate models. There exist many copula functions,
each with its own unique properties that allow it to model different dependence structures. For
example, the Frank copula (170) exhibits weak dependence in both tails. One of the most
common classes of copula functions, Archimedean copulas, is described below.

2.3.3.1

Archimedean copulas

Archimedean copulas encompass a variety of copula functions that can all be characterized by an
explicit formula. Archimedean copulas are commonly the preferred method of dependence
modelling due to their ability to model dependence in arbitrarily high dimensions with a single
parameter that governs the strength of the dependence (167,168). Archimedean copulas follow
the structure:
𝐶(𝑢1 , … , 𝑢𝑑 ; 𝜃) = 𝜓 [−1] (𝜓(𝑢1 ; 𝜃) + ⋯ + 𝜓(𝑢𝑑 ; 𝜃); 𝜃)
where θ is a parameter within some parameter space Θ, ψ is the generator function (a function
unique to the copula used), and 𝜓 [−1] is its pseudo-inverse given as:
𝜓 [−1] (𝑡; 𝜃) = {

𝜓 −1 (𝑡; 𝜃) if 0 ≤ 𝑡 ≤ 𝜓(0; 𝜃)
0 if 𝜓(0; 𝜃) ≤ 𝑡 ≤ ∞.

As seen, the generator function determines the copula function; θ must be estimated based on the
dependence that exists between variables. Larger values of θ correspond to larger amounts of
dependence between diseases.
For example, the generator function for the Gumbel copula is (171):
(− log(𝑡))𝜃
which gives the following function:
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1

𝐶𝜃 (𝑢, 𝑣) = exp [−((− log(𝑢))𝜃 + (− log(𝑣))𝜃 )𝜃 ]
where θ  [1, )
The Gumbel copula (171) is an asymmetric copula that exhibits greater dependence in the
positive tail than in the negative tail. Other examples include the Frank copula (170), which is a
symmetric copula that is used to model weak dependence and the Clayton copula (172), which is
an asymmetric copula function that exhibits greater dependence in the negative tail than in the
positive. Many other copula functions exist, each with its own unique properties.
Copulas have been used commonly in finance, where financial distributions often are nonnormal. For example, copulas have been used extensively in the area of financial risk
management (54). During a recession, investors who hold positions in riskier assets, such as real
estate, may move their investments into safer alternatives, such as cash or bonds. This trend
results in an asymmetric distribution, where correlations across equities are greater in the
downward direction compared to the upward direction. Copulas aid by modelling the marginal
distributions separately from the dependence structure. In this example, marginal models can
describe the behaviour of individual investors. However, the actions of one investor are not
independent of those of other investors; thus, copulas allow the modelling of the behaviour of
investors while considering the actions of other investors. Copulas have also been used in the
areas of engineering (55), neuroscience (56,57), and climate and weather research (58,59).

2.4

Electronic Medical Records

As mentioned, one potential source of data for the development of a PPM for multiple diseases is
EMR data. Explained in greater detail below, these data sources contain the medical records,
including diagnoses, prescriptions, treatments and laboratory results, of thousands of patients that
may enable the estimation of the risk of multiple diseases.

2.4.1

Overview

Electronic medical records (EMRs) are software programs used to store patient information
electronically. Traditionally, patient information has been stored in paper records; however, there
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has been a shift from using paper records for this purpose to using EMRs (173). The goal of an
EMR is to support the delivery of quality care by providing accessible and structured storage of
information. These digital records contain individual patient information describing
demographics, medical history, medications, allergies, laboratory test results, radiology images,
vital signs, patient characteristics such as height and weight, risk factor information, and billing
information (174).
Data are stored within an EMR in a variety of ways. Data can be stored in a highly structured
manner, such as pick-lists or drop-down menus, or highly unstructured manner, such as free-text.
For example, disease information such as a diagnosis of diabetes may be included in the EMR as
an entry in the billing table or problem list with the corresponding International Classification of
Disease (ICD) code. Alternatively, a diagnosis of diabetes could simply be noted in the free-text
narrative portion. Indeed, there are often multiple ways to store the same information within the
EMR (175); thus, data of interest may be found in multiple locations within the EMR. All data
within the record have an associated date and time, allowing PCPs to look back in the record to
observe changes over time.
EMRs support many functions beyond the mere storage and retrieval of information, including
billing services, appointment scheduling, referral services, laboratory test requisitions, and
medication prescriptions (173,174). Furthermore, EMRs often support other functions known as
decision support tools. Examples of these tools include medication interaction tools, which alert
PCPs to potential interactions between medications when prescribing (176); clinical guidelines,
which provide easy access to evidence-based guidelines (177); and risk assessments, which
estimate a patient’s risk of experiencing some future outcome (178).
EMRs are commonly developed and maintained by private vendors; however, open source
options, such as OSCAR (179), exist. Canada does not have one single EMR software program,
as health care is managed at the provincial and territorial levels. Instead, several EMR vendors
exist, each with their own EMR software, competing for PCP and hospital business. As a result,
there is no single repository containing the health records of all Canadians.
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2.4.2

Uptake of EMRs in Canada

The current rate of EMR use in Canada is more than twice that of 2009; thirty seven percent of
PCPs used an EMR to store patient information in 2009, whereas 73% of PCPs reported doing so
in 2015 (180). While this recent increase in uptake is promising, Canada still falls below the
international average by 15% (180). Provincial rates were found to be quite variable, with
Alberta at 85% adoption and New Brunswick at 40% adoption (180). Given their level of use
and potential to support clinical care, the extent to which EMRs are being utilized has been
examined. Only 41% of Canadian PCPs use EMRs to support quality of care decisions, such as
drug interaction tools or reminders for regular care or screening tests, compared to 58%
internationally (180).

2.4.3

Use of EMRs for Research Purposes

EMRs represent a rich source of information describing a patient’s health and health care. EMR
databases can be linked together to form large repositories of patient information that allow for
health surveillance to inform clinical and epidemiological research, public health interventions,
health care planning, and quality assurance. For example, the Canadian Primary Care Sentinel
Surveillance Network (CPCSSN) is a collection of EMR databases from across Canada that
contains primary care information on more than 1.5 million patients (181). This database has
been used for surveillance of chronic diseases including hypertension (92), depression (182), and
diabetes (59). Information are only recorded in an EMR where deemed clinically relevant by the
EMR user; information such as physical activity, occupation, ethnicity, family history or other
characteristics that may be important for research purposes are often not noted in EMRs.
However, an EMR is a great source of population-level data pertaining to patient characteristics
including diagnoses, laboratory results, medication prescriptions, and referral patterns.
The form that data are recorded in the database greatly impacts its utility for research purposes.
Data are readily analyzed when stored in a structured form that arises from the use of drop-down
boxes or pick-lists. When data are stored in the form of a free-text narrative, methods such as
natural language processing (183) must be used to extract information from the data. One
suggested method of improving the usability of EMR databases for research is to encourage
PCPs to engage in consistent and accurate coding of patient information (184).
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EMR data only describe the population receiving primary care, not necessarily the general
population. A study looking at the representativeness of the CPCSSN national database found
that, compared to data from the 2011 census, CPCSSN patients were somewhat representative of
the Canadian population (185). CPCSSN patients were roughly 4 years older on average and less
likely to be male, making it is necessary to adjust for age and sex to generalize results based on
CPCSSN data to the general population. When applying EMR data to a primary care population,
no adjustment is necessary.
EMR data are limited by their use of diagnostic codes as proxies for health events, such as
disease development. For a symptom or disease to be successfully captured within an EMR, the
patient or PCP must recognize and report the symptom or disease; subsequently, the practitioner
must know the proper code and record this in the EMR. Any break in this stream of events will
result in failure to capture the information. This has implications for research using EMR data,
where the absence of a diagnostic code is often interpreted as the absence of disease. The extent
to which this impacts results depends on how well diagnoses of disease are recorded in the EMR.
Diseases with more significant and clearly defined diagnostic features, such as diabetes, are
better recorded within the EMR (186). The use of diagnostic codes is also problematic as
diagnostic codes are not always able to fully capture the complexities of chronic diseases.
Compared to alternative sources of health information, such as health administrative data or
primary data collection from observational studies, EMR data are both rich and numerous.
Despite describing the health of the majority of the population in Canada, health administrative
data are limited by what is captured; for example, only billing codes for the “most responsible
diagnosis” are stored in health administrative databases (187). EMR databases can be used to
overcome this limitation as they contain a rich history of patients’ health, including past and
current diagnoses, medications, laboratory results, and radiographic images (174). In Canada,
EMR databases do not contain records of the entire population, whereas health administrative
databases contain data wherever a patient has received care due to the remuneration methods
employed in Canada; however, the data that are collected in EMR repositories such as CPCSSN
are often sufficient to allow for analyses at the provincial and national levels (185). Primary data
collection obtains precisely what patient characteristics are of interest using a consistent method
or measure; comparatively, EMR data are only collected where clinically relevant and often do
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not describe the measure used (175). Primary data collection, however, requires significantly
greater resources when compared to EMR data (188), where the data have been previously
collected.

Table 1: Comparison of Data Sources
EMR

Observational Studies

Health Administrative
Data

Large sample size

Small sample size

Large sample size

Contain all diagnostic
codes recorded in a single
encounter

-

Contain only one diagnostic
code per encounter

Collect only data deemed
clinically relevant

Collect all data of interest

Collect only data deemed
necessary for
administration/billing

Measurement method
unknown

Data collected using a
standardized measure

Measurement method
unknown

2.5

Summary

The current literature demonstrates the need for novel techniques aimed at the prevention of
chronic disease. In particular, multimorbidity is a pressing concern for which prevention
techniques remain underdeveloped. Prognostic predictive models present an opportunity for such
a technique that might allow insight into a patient’s risk of multimorbidity. Such insight might
allow for targeted interventions aimed at reducing patient risk. EMRs may contain the data
needed for the development of these models, as these data sources contain health information of
numerous patients over time.
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Chapter 3

3

Methods

The following chapter describes the development of a prognostic PPM for multiple chronic
diseases using data from EMRs. Logistic regression and copula modelling were used in model
development.

3.1

Data Source

Data were derived from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN)
database (181). Initially formed in 2008 through funding provided by the Public Health Agency
of Canada (PHAC), this nation-wide database contains patient information from EMRs of
primary care practices across Canada (184). The objective of this network is to enable both the
surveillance of chronic disease and primary care research at a national level. CPCSSN aims to
accomplish these goals by collecting clinical data that provide insight into the health of
Canadians from a primary care perspective through clinical and epidemiological research.

Figure 2: CPCSSN Structure
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The CPCSSN database follows a hierarchical structure: individual patient encounters (visits with
their PCP) are collected for each patient; these encounters are grouped by patients involved in
these encounters; which are grouped by the PCP from which they receive care; which are
grouped by the primary health care (PHC) site in which they practice; which are grouped by the
network to which they contribute their data; which are then contained within the CPCSSN
database. Originally involving 7 academic primary care research networks across 4 provinces
(Newfoundland, Quebec, Ontario, and Alberta) (184), the CPCSSN database now involves 12
regional networks across 8 provinces and territories. Initial recruitment of practices occurred
from 2008 to 2010, in which family practices (mostly those associated with academic or
university sites, as these were more likely to participate in research) were recruited to contribute
their data to the CPCSSN database. Following this initial period, recruitment expanded to
include non-academic practices in various settings (urban, suburban, and rural). Past and ongoing
patient consent was obtained via an opt-out system, in which patients who do not wish for their
information to be contributed to the database may choose to opt out; all provinces operate under
this system, except for Quebec, where an opt-in process is mandated by provincial law. Within
these regional networks are 218 practices. Ontario, as one of the founding and most populated
provinces, has the greatest number of participating practices. British Columbia and Quebec make
smaller contributions as British Columbia is a relatively new network and legislative
requirements in Quebec deter the process. The CPCSSN database contains records from 1189
PCPs. Data describing the nature of PCP’s practice, such as profession (i.e. physician or nurse
practitioner) or payment model (e.g. fee-for-service or capacitation), are unavailable for most
PCPs. CPCSSN contains deidentified records of more than 1.5 million patients, making it the
largest source of primary care information available in Canada.
The CPCSSN database is comprised of several data tables containing information pertaining to
either the practice, provider, patient, or patient encounter. For example, the Billing table contains
all ICD-9 codes used by the provider to submit a billing claim; these data can be used to identify
diagnoses made by the provider. Note, however, that providers are limited to one diagnosis per
patient encounter, thus the diagnosis recorded is known as the most responsible diagnosis. The
Health Condition table contains additional diagnoses made during an encounter, regardless of
whether they were billed for; this is congruent with the problem list used in other EMRs. From
the tables contained within CPCSSN, all structured patient records can be extracted, including
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patient demographics, billing codes, laboratory results, prescriptions, referrals, risk factor
information, medical procedures, vaccinations, and allergies. For privacy reasons, the free-text
narrative where PCPs record their notes is not available in CPCSSN. Tables were linked using an
identifier unique to each patient.
Table 2: CPCSSN Data Tables
Table Name
Billing
Health Condition

Contents
Diagnoses
Diagnoses

Encounter Diagnosis

Diagnoses

Patient

Age
Sex
Occupation
Highest education
Housing status
Forward Sortation Area
(FSA)
Language
Ethnicity
Laboratory results
Examination results
Medication prescriptions
Reported family history
Reported risk factors
Medical procedures
Referrals
Vaccines received
Allergies and intolerances
Validated cases of disease
Age
Sex
Group type
Payment model
Province

Patient Demographic

Lab
Exam
Medication
Family History
Risk Factor
Medical Procedure
Referral
Vaccine
Allergy/Intolerance
Disease Case
Provider
(Provider) Group Info
Site

Format
ICD-9 Codes
ICD-9 Codes
Free text
ICD-9 Codes
Free Text
Numeric
Text
Text
Text
Text
Text

Completeness
-

Text
Text
Numeric
Numeric
Text
Text
Text
Text
Text
Text
Text
Text
Numeric
Text
Text
Text
Text

14.1%
1.0%
87.8%
98.3%
75.9%
3.4%
100%

99.8%
99.9%
5.1%
2.0%
4.4%
95.4%

Due to the volunteer basis of practice recruitment, the CPCSSN database can be seen as a
convenience sample of primary care patients across Canada. CPCSSN patients are somewhat
representative of the Canadian general population (185). Provincial-level comparisons are
appropriate for all included provinces, except for British Columbia and Quebec due to their low
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participation (185). As of 2013, CPCSSN patients were older and more likely to be female
compared to the overall Canadian population as reported in census data. Research has
demonstrated that this trend is typical of primary care (189–191). Compared to practitioners
responding to the National Physician Survey, CPCSSN practitioners were younger, more likely
to be female (51.1 vs. 44.0%), and from an academic practice (19.3% vs. 7.8%) (185).
First, the construction of a PPM requires an understanding of what risk factors are known to
increase the risk of disease development. Next, a cohort of people whose risk factor status at
baseline and their subsequent disease outcome are known is needed. From this cohort,
multivariable models are built to describe the associations between each risk factor and the
disease outcome.

3.2
3.2.1

Measures
Outcome

The following diseases were predicted simultaneously: diabetes, hypertension, and osteoarthritis.
These diseases were selected based on several criteria. First, the selected diseases are among the
most prevalent in Canada (53,192). Previously validated case-detecting algorithms for use with
EMR data exist for these diseases (described more fully below) (193). These diseases are often
diagnosed and treated in primary care (54,85,105). Each of these diseases have modifiable risk
factors, some of which overlap between diseases (35,36,63,70). Finally, expert consultation
revealed that risk estimations for the selected diseases, in particular their co-occurrence, would
be clinically useful. In this work, recovery from disease was considered not possible; once a
patient has one of the diseases, they will always have the disease.
Chronic pain and asthma were also among the most prevalent diseases; however, neither have a
validated case-detecting algorithm.
One initiative of CPCSSN researchers has been to develop and validate case detecting algorithms
for several chronic diseases that can be used to identify cases of disease within the database
(193). In an effort to facilitate quality research, CPCSSN has created disease case-detecting
algorithms for osteoarthritis, depression, hypertension, diabetes, chronic obstructive pulmonary
disease (COPD), epilepsy, Parkinson’s disease, and dementia. These case-detecting algorithms
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are composed of information including ICD-9 codes within the billing or problem list;
medication prescriptions; laboratory results; or any combination of these elements. Construction
of the case-detecting algorithms was informed by published evidence and input from both
primary care and specialist physicians. Subsequently, each disease case-detecting algorithm was
validated by chart review. Chart review was performed by research assistants blinded to the
diagnosis assigned by the algorithm. Reviewers determined the absence of disease through
examination of the entire electronic medical record. Where a reviewer was uncertain, the study
epidemiologist and a physician from the study team performed a chart review. The ability of the
case-detecting algorithm to correctly assign diagnoses was assessed by comparing its results to
those of the chart review, resulting in both sensitivity and specificity statistics. Sensitivity and
specificity for all diseases were high (Appendix A). In this thesis, diagnoses of diabetes,
hypertension, and osteoarthritis were identified using the case-detecting algorithms developed by
CPCSSN researchers.
The use of validated disease case-detecting algorithms helps ensure that the identification of
disease cases is accurate. This is especially important as inaccuracy in the identification of the
disease will decrease a predictive model’s performance due to incorrect estimation of the
relationships between the predictors and actual disease development. This poor performance
would not be revealed by internal validation because the data used for validation would be
subject to the same issue of inaccuracy in disease identification as the data used for constructing
the model. Often only internal validation is feasible, reinforcing the importance of using a
validated case-detecting algorithm for the identification of disease cases. However, the
correctness of predictors is not as crucial, since the main goal of this analysis was not etiologic
research, but the prediction of future disease development. For example, a diagnosis of
osteoporosis is a risk factor for osteoarthritis; however, the ICD-9 code used for osteoporosis
also includes several other bone disorders. Despite this ICD-9 code not being specific to
osteoporosis, it is still useful as a predictor for osteoarthritis because its presence in patient’s
EMR was found to be significantly associated with future development of osteoarthritis.
Accordingly, caution must be taken when making causal inferences from the resulting predictive
model since the model does not truly describe the impact of an osteoporosis diagnosis on risk of
osteoarthritis, but rather the impact of the presence of the ICD-9 code.
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As both predictor and outcome assessment was done by the PCP, blinding did not occur during
outcome assessment, which may have introduced measurement bias. This issue is present in all
EMR and health administrative data due to the nature of the data. However, the diseases
predicted are common conditions with clearly identifiable diagnostic criteria, thus skilled PCPs
should be able to diagnose cases of disease with a high degree of accuracy, limiting the influence
of knowledge of predictor status at baseline on this assessment, and in turn limiting the amount
of bias introduced.

3.2.2

Predictors

Predictors for each of the three diseases to be predicted were identified through review of the
relevant literature.
Table 3: Disease Predictors
Diabetes
Hypertension (36,63)
Older age (36,63)
Lipid disorders (36)
Obesity (35,36,63,70)
Waist circumference
Smoking (36,63)
Stress (36)
Male sex (36)
Polycystic ovarian
syndrome (PCOS) (64)
Schizophrenia (65,66)
Depression (67)
Bipolar disorder (66,68)
Low physical activity (70)
Family history of type 2
diabetes (36)
Air pollution (69)
Low socioeconomic status
(70)

Hypertension
Older age (93)
Diabetes (93,94)
Obesity (93,94)
Smoking (93)
Stress (97)
Kidney disease (95)
Tricyclic antidepressant
(TCA) use (98)
High salt intake (93,99)
Sleep apnea (96)

Osteoarthritis
Osteoporosis (39)
Previous leg injury
(38,40,117,119)
Leg length inequality (115)
Older age (39,40,116–118)
Obesity (38–40,116–119)
Female sex (39,40,116,117)
Family history of
osteoarthritis (116)
Physically intensive
occupations (116)

Table 4: Shared Risk Factors
Older age
Obesity

Diabetes
X
X

Hypertension Osteoarthritis
X
X
X
X
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Smoking
Stress
Hypertension
Lipid disorders
Waist circumference
Male sex
Female sex
PCOS
Schizophrenia
Depression
Bipolar disorder
Low physical
activity
Air pollution
Low socioeconomic
status
Diabetes
Kidney disease
Tricyclic
antidepressant use
High salt intake
Sleep apnea
Osteoporosis
Previous leg injury
Leg length
inequality
Family history of
type 2 diabetes
Family history of
osteoarthritis
Physically intensive
occupations

X
X
X
X
X
X

X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

For each predictor, an algorithm for the identification of each risk factor was developed. Where a
CPCSSN validated case-detecting algorithm was available, this was used; otherwise the
following process was used to identify information that described the predictor. First, the
CPCSSN data dictionary (181) was examined to determine if any fields contained information
describing the predictor exactly (for example, BMI was found in the exam table). Next, other
methods of detecting the predictor were identified, then investigated for their presence within
CPCSSN. These included diagnostic terms and ICD-9 codes; medications used specifically to
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treat a given condition; and laboratory test results indicative of a given condition (for example,
an LDL measurement between 3.37 and 9 mmol/L was indicative of a lipid disorder). All
diagnostic codes in the CPCSSN database are stored as ICD-9 codes, thus only ICD-9 codes
were used. Multiple inclusion terms were used to capture all terminologies used to describe the
condition; additionally, exclusion terms were used to exclude those that did not describe the
condition. All methods of identifying predictors were reviewed by a PCP who was a member of
the study team to ensure accuracy (for example, the PCP ensured that all medications used to
identify predictors are medications only prescribed for the predictor condition). Subsequently,
predictor information was compiled into predictor case-detecting algorithms that would be used
to identify cases of predictor presence. Case definitions for each risk factor can be found in
Appendix B.
An estimate of income was obtained using the Forward Sortation Area (FSA) available for most
patients. Full postal codes are unavailable in the CPCSSN data for privacy reasons. Each
patient’s FSA, where available, was matched to average personal income according to the
National Household Survey (NHS) conducted in 2011 (194). Similarly, rurality was based on
postal code. The second digit of a postal code is used to denote whether the area is urban or rural.
A zero indicates that the area is rural, while all other digits indicate urban areas (195). Where the
second digit of the FSA was zero, the patient was considered to live in a rural area.
Interaction terms were considered; however, no interactions were suggested in the existing
literature (196).
As suggested in TRIPOD (150), all continuous risk factors were kept in their original form,
rather than binning them into categories, in order to maximize the amount of information
available for each covariate.

3.3

Participants

Participants were drawn from the CPCSSN primary care database. The PPM that was developed
for this thesis is intended to be deployed in primary care in Canada to address risk of multiple
diseases in adults. All patients aged 18 or older were included in the cohort, irrespective of prior
morbidities. Patients who have previously been diagnosed with all three diseases (diabetes,
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hypertension, and osteoarthritis) were excluded, as these patients were not at risk of developing
any of these diseases. All eligible patients were considered for analysis.

3.4

Sample Size Considerations

The retrospective cohort made use of all available patient data; no sub-sampling of the CPCSSN
database was done. The cohort was split into two partitions: one for model development and one
for validation.
Often the minimum required size for each partition to be confident in risk estimations is
determined by an anecdotal heuristic stating that for each predictor, there should be at least 10
events (in this case, 10 patients who develop the disease(s) of interest). This method has been
commonly criticized for the lack of evidence supporting its use (197). However, no method has
been agreed upon to determine the sufficient number of events per variable; thus, in order to
maximize the number of events per variable, predictors were only selected for use where external
evidence of an association existed.

3.5

Cohort Construction

From the time-stamped records, a retrospective cohort was constructed. To begin, all patients
listed in the patient table were considered. Patient “recruitment” began 1 January 2009 and ended
31 December 2010 (a period of two years); patients who had any EMR entry (billing occurrence,
encounter recording, encounter diagnosis, exam recording, or health condition recording) in the
recruitment time period were included. For each patient, the date of the first record within the
recruitment time period was considered the patient’s unique start-date. At this point, predictors
(including diabetes, hypertension, and osteoarthritis, as one may predict for another) were
assessed using the disease and predictor case definitions (Appendix B). Patients who had been
previously diagnosed with all 3 diseases were excluded, as these patients were not at risk of
developing the diseases. Additionally, patients younger than 18 years of age were excluded. Any
diagnoses of disease within the subsequent 5-year period were noted.
The cohort was randomly divided into development and validation datasets at approximately a
2:1 ratio: the development set for model selection and parameter estimation and the validation set
for assessing discrimination and calibration of the resulting model.
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3.6

Missing Data

As data in an EMR are collected for clinical purposes, not specifically for research use, data are
often missing from the EMR because they are not relevant for patient care, despite being highly
relevant for research. Data can be missing in a variety of ways. Data can be missing completely
at random (MCAR), where the reason that the data are missing is independent of all other
variables, observed or unobserved (198). For example, data that are artificially sub-sampled at
random would be MCAR. Where data are MCAR and must be omitted from analysis, analyses
have less power but remain unbiased. Data are missing at random (MAR) when their
missingness can be explained by the value of observed variables (198). For example, a lab test
result for cholesterol may be missing because a patient is observed to be young and have normal
BMI. Where data are MAR, techniques can be used to impute missing data using strategies that
minimize the amount of bias that is introduced. Data are missing not at random (MNAR) where
their missingness is dependent upon some unobserved variable, including the missing variable
itself (198). For example, a blood pressure measurement may not be recorded because it is within
normal ranges. Analyses based on MNAR missing data will produce biased results (198). Most
methods to address missing data assume data to be MAR; the validity of this assumption impacts
the amount of bias introduced into analyses.
Imputation is the process of replacing missing values with plausible values. Depending on how
the data are missing, different imputation methods can be used. Common examples of imputation
include last observation carried forward (199), in which the missing value is replaced with the
last value that was observed; mean substitution (199), in which the missing value is replaced
with the mean of the characteristic’s observed values; and regression (199), in which other
observed characteristics of the individual are used to estimate a value for the missing value.
These methods are single imputation methods, which do not account for the uncertainty in the
imputed values (200). In contrast, multiple imputation can be used to replace missing values
while accounting for the uncertainty in the imputations by creating multiple estimates for the
missing value (200). In multiple imputation, several values are estimated for the missing value,
creating multiple imputed datasets. There are several methods of multiple imputation. For this
work, multiple imputation by chained equations (MICE) was used. MICE follows these steps, as
described by Azul et al. (201): 1) A simple imputation, such as mean substitution, is used to
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complete all missing values. These imputed values should be thought of as placeholders. 2) One
variable with missing data is selected as the variable of interest, var. The values for var that were
originally missing are set back to missing. 3) These now missing values are imputed using
regression based on all variables, including those containing placeholders. Var can be thought of
as the dependent variable, for which the other variables serve as independent variables.
Subsequent imputations using var as an independent variable for other variables will use these
imputed values. 4) Steps 2 & 3 are repeated for each variable with missing data. Imputed values
from previous cycles are used instead of the placeholders. 5) Steps 2 through 4 will be repeated a
given number of times, updating the imputations each time, resulting in multiple imputed
datasets.
Multiple imputation was used for this study, which produced multiple completed datasets. While
a single point estimate will be presented for each statistic, in actuality, several were computed
(one for each imputed dataset); these results were then combined using Rubin’s rules (200) to
create a single statistic whose variance has been adjusted to account for the uncertainty of
deriving an estimate from multiple datasets.

3.7

Statistical Analysis

To facilitate the construction of a PPM for diabetes, hypertension, and osteoarthritis, an analysis
of the dependence between these diseases was performed. As described above, copulas were
selected to model the dependence between diseases because of their ability to account for more
than two diseases, adjust for both continuous and discrete variables, and ultimately be used to
construct a PPM. The steps in dependence modelling using copulas are: 1) univariate (marginal)
models are constructed for each outcome and 2) copulas are used to describe the dependence
between outcomes (202,203).

3.7.1

Univariate Multivariable Logistic Regression

To address Objective 1, univariate multivariable logistic regression models of the development
of each disease were constructed. Three univariate models were produced, one for each disease
to estimate its marginal distribution. For each disease, a subgroup of the development cohort who
were free of the disease being predicted at baseline were included in the estimation of the
univariate model. For example, a subgroup of patients who did not have diabetes at baseline
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were used to construct the diabetes univariate model. The 𝛽̂𝑖 coefficient estimates of each model
are presented along with 95% confidence intervals for the 𝛽𝑖 . Internal validation assessing
discrimination and calibration was performed. Discrimination refers to the ability of the model to
assign a higher estimated risk to a person who ultimately experiences the outcome compared to a
person who does not. For discrimination, models were assessed by calculating the area under the
receiver operator characteristic curve (AUC). Calibration examines how well the model fits the
data. For calibration, models were assessed by constructing calibration plots. As the dataset was
extremely large, methods such as cross-validation (161) or bootstrapping (162) were not
necessary; instead, discrimination and calibration were assessed using the validation set.

3.7.2

Analysis of Dependence

To address Objective 2, an analysis of the dependence between each outcome was conducted
both with and without adjustment for risk factors, in a purely descriptive (non-predictive)
framework and then in a predictive framework. Each analysis of dependence was conducted in a
pairwise fashion; specifically, the dependence between diabetes and hypertension, diabetes and
osteoarthritis, and hypertension and osteoarthritis was estimated. To be included in a pairwise
analysis, a patient had to be free of both diseases under investigation at baseline. For example,
only patients free of both diabetes and hypertension at baseline were included in any analysis of
the dependence between diabetes and hypertension.
To begin, the pairwise unadjusted correlation between each outcome was measured using the ϕ
coefficient (also known as the mean square contingency coefficient). The ϕ coefficient is a
measure of association between two binary variables, similar to the Pearson correlation
coefficient for continuous variables (204). In fact, estimating a Pearson correlation coefficient for
two binary variables gives the ϕ coefficient (204). Pairwise ϕ coefficients were calculated along
with the corresponding test statistic and 95% confidence interval.
Partial correlation examines the correlation that exists between variables after adjusting for the
effect of other variables; again, this is measured using the ϕ coefficient. Partial correlations were
determined for each outcome pair, adjusted for the combined risk factors for each outcome using
the function pcor from the ppcor R package (205).
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Subsequently, copulas were used to describe the dependence between outcomes. The choice of
copula was determined by the structure of the dependence. For this study, the Frank copula (170)
was selected for used based on its ability to capture weak dependence. When modelling the
dependence between binary variables, the copula is defined by both θ and the marginal
distributions (202). As such, the two-stage estimation procedure based on the composite
likelihood suggested by Zhao and Joe (203) was used for the estimation of θ. First, the marginal
models were determined using the maximum likelihood estimation procedure. This step yielded
β estimates that were used in the second step. From these univariate models, the probabilities for
the independent occurrence of each outcome were estimated, by:

𝜋𝑗 (𝐱) =

exp(𝐱 T 𝜷𝒋 )
1 + exp(𝐱 T 𝜷𝒋 )

where 𝜷𝒋 is a vector containing the β estimates for each outcome j and x is a matrix of covariate
data. Second, estimates of θ were obtained, again using the maximum likelihood estimation
procedure. This process made use of the bivariate conditional distributions of each outcome pair.
From these, the likelihood function was constructed. By setting the derivative of the log
likelihood function (known as the score function, 𝑠𝜃 ) equal to zero, θ was estimated.
𝑛

𝑠𝜃 (𝜃, 𝛽𝑘 , 𝛽𝑙 ) = ∑ 𝐶𝜃̇ (𝜋̅𝑖𝑘 , 𝜋̅𝑖𝑙 ) (
𝑖=1

+

(1 − 𝑌𝑖𝑘 )(1 − 𝑌𝑖𝑙 )
(1 − 𝑌𝑖𝑘 )𝑌𝑖𝑙
𝑌𝑖𝑘 (1 − 𝑌𝑖𝑙 )
−
−
𝐶𝜃 (𝜋̅𝑖𝑘 , 𝜋̅𝑖𝑙 )
𝜋̅𝑖𝑘 − 𝐶𝜃 (𝜋̅𝑖𝑘 , 𝜋̅𝑖𝑙 ) 𝜋̅𝑖𝑙 − 𝐶𝜃 (𝜋̅𝑖𝑘 , 𝜋̅𝑖𝑙 )

𝑌𝑖𝑘 𝑌𝑖𝑙
)
1 − 𝜋̅𝑖𝑘 − 𝜋̅𝑖𝑙 + 𝐶𝜃 (𝜋̅𝑖𝑘 , 𝜋̅𝑖𝑙 )

𝑒 𝜃 𝜃((𝑢 − 1)(−𝑒 𝜃𝑣 )−𝑒 𝜃(𝑢+𝑣) + 𝑢𝑒 𝜃𝑣+𝜃 − (𝑣 − 1)𝑒 𝜃𝑢 + 𝑣𝑒 𝜃𝑢+𝜃 − 𝑒 𝜃 (𝑢 + 𝑣) + 𝑢 + 𝑣 − 1)
(𝑒 −𝜃𝑢 − 1)(𝑒 −𝜃𝑣 − 1)
+ ln (
+ 1)
𝑒 −𝜃 − 1
(𝑒 𝜃 − 1)(−𝑒 𝜃(𝑢+𝑣) + 𝑒 𝜃𝑢+𝜃 + 𝑒 𝜃𝑣+𝜃 − 𝑒 𝜃 )
𝐶𝜃̇ (𝑢, 𝑣) =
2
𝜃

𝜋̅𝑖𝑘 = 1 − 𝜋𝑖𝑘
𝜋̅𝑖𝑙 = 1 − 𝜋𝑖𝑙
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where 𝐶𝜃 is the copula function; 𝐶𝜃̇ is the derivative of the copula function; 𝜋𝑖𝑘 and 𝜋𝑖𝑙 are
estimated probabilities of disease k and l for patient i based on their univariate models,
respectively; and 𝑌𝑖𝑘 and 𝑌𝑖𝑙 are the observed disease outcomes for patient i.
A dependence structure using copulas is completely specified by its univariate multivariable
models and copula, which is specified by its θ estimate. Estimates of the parameter θ were
obtained for each disease pair. Bootstrapping was used to construct confidence intervals for the θ
estimates; the percentile method was used (206), in which the sample means at the 2.5 and 97.5
percentiles were used to approximate the confidence interval based on one thousand
bootstrapped replicates. Additionally, the following hypothesis test based on the score test was
used to test the null hypothesis that the observed outcome frequencies are no different than what
would be expected under independence (202). The null hypothesis was rejected if 𝓏𝑜𝑏𝑠 is larger
in absolute value than a critical value derived from the standard Normal distribution, denoted
N(0,1).
𝑛

𝓏𝑜𝑏𝑠

𝑛
𝐶𝜃̇ 20 (𝜋̅̂𝑖𝑘 𝜋̅̂𝑖𝑙 )
𝐶𝜃̇ 0 (𝜋̅̂𝑖𝑘 , 𝜋̅̂𝑖𝑙 )(𝑌𝑖𝑘 − 𝜋̂𝑖𝑘 )(𝑌𝑖𝑙 − 𝜋̂𝑖𝑙 )
=∑
/√∑
𝜋̂𝑖𝑘 𝜋̂𝑖𝑙 𝜋̅̂𝑖𝑘 𝜋̅̂𝑖𝑙
𝜋̂𝑖𝑘 𝜋̂𝑖𝑙 𝜋̅̂𝑖𝑘 𝜋̅̂𝑖𝑙
𝑖=1

𝑖=1

Based on these copula models, trivariate probabilities that account for the dependence between
outcomes can be estimated; that is, the probabilities of each combination of diseases will be
estimated. Each trivariate probability can be described as a probability mass function.
𝑝(𝑥1 , 𝑥2 , 𝑥3 ) = 𝑝(𝑋1 = 𝑥1 , 𝑋2 = 𝑥2 , 𝑋3 = 𝑥3 )
Bivariate probability mass functions can be used to describe the marginal distributions of the
trivariate probability mass functions.
𝑝(𝑥1 , 𝑥2 ) =

∑ 𝑝(𝑥1 , 𝑥2 , 𝑥3 )
𝑥3 ∈ {0,1}

Similar expressions are true for 𝑝(𝑥1 , 𝑥3 ) and 𝑝(𝑥2 , 𝑥3 ). Based on 𝑝̂ (𝑥1 , 𝑥2 ), 𝑝̂ (𝑥1 , 𝑥3 ), and
𝑝̂ (𝑥2 , 𝑥3 ) as estimated by the copula model, trivariate probability mass functions (𝑝̂ (𝑥1 , 𝑥2 , 𝑥3 ))
can be found that satisfy the bivariate marginal distributions. In fact, there may be many
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combinations of trivariate probability mass functions that satisfy this relationship; the
combination with the highest entropy (207) (highest uncertainty) was chosen, as this gives the
most conservative estimate. From this analysis, the trivariate probabilities can be estimated. For
example, the risk of developing diabetes, hypertension, and osteoarthritis all within a 5-year
window can be estimated.
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Chapter 4

4

Results

The following chapter first provides descriptive statistics about the study cohort. This is followed
by the analysis of dependence using copulas. First, the univariate multivariable logistic
regression models are presented. Next, both unadjusted and adjusted dependence analyses,
including the copulas, are presented. Finally, the copulas are used to estimate the risk of multiple
diseases for two simulated patients.

4.1

Descriptive Statistics

A cohort of 425228 adult patients who did not have comorbid diabetes, hypertension, and
osteoarthritis who had received care between 1 January 2009 and 31 December 2010 were
followed for 5 years. Figure 4 details the flow of patients into the cohort. The final cohort was
split into a development set of 265228 patients (62%) and a validation set of 160000 patients
(38%). Most patients began the period of study without morbidities (70%) (the following
diseases were considered when assessing morbidities: asthma, arthritis, COPD, diabetes,
cardiovascular disease, mental disorder (mood disorder and/or anxiety), Alzheimer's disease and
related dementias, cancer, and stroke). The most common condition was having a lipid disorder
(17.9%). The majority of patients were female (58.1%), which is typical of a primary care
population (189–191). The average age of patients was 47.1 years old (standard deviation: 18.0
years). Most patients were overweight or obese (64.1%). After the 5-year period, hypertension
was the most commonly acquired disease, with an incidence proportion of 9.4% and an incidence
rate of 0.0818 events/person-year, followed by diabetes with an incidence proportion of 4.4%
and an incidence rate of 0.0413 events/person-year. Osteoarthritis was developed by the least
number of patients, with an incidence proportion of 3.0% and an incidence rate of 0.0248
events/person-year. No significant differences between the development and validation sets were
observed. For a detailed description of all patient characteristics, see Table 6; note that each
percentage denotes the percent of patients with the risk factor among those who had complete
information for that risk factor. Each risk factor has been compared to its national prevalence
from approximately 2010.
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Figure 3: Cohort Construction
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Table 5: Incidence of Diabetes, Hypertension, and Osteoarthritis
Entire Cohort (n =
425228)
Diabetes
Incidence
Proportion, n (%)
Incidence rate,
events/person-year
(95% CI)
Hypertension
Incidence
Proportion, n (%)
Incidence rate,
events/person-year
(95% CI)
Osteoarthritis
Incidence
Proportion, n (%)
Incidence rate,
events/person-year
(95% CI)

Development Set (n
= 265228)

Validation Set (n =
160000)

18769
(4.4%)
0.0415
(0.0409 to 0.0421)

11677
(4.4%)
0.0413
(0.0406 to 0.0421)

7092
(4.4%)
0.0418
(0.0408 to 0.0428)

39882
(9.4%)
0.0818
(0.0810 to 0.0826)

24828
(9.4%)
0.0816
(0.0806 to 0.0827)

15054
(9.4%)
0.0820
(0.0807 to 0.0833)

12803
(3.0%)
0.0248
(0.0243 to 0.0252)

7980
(3.0%)
0.0248
(0.0242 to 0.0253)

4823
(3.0%)
0.0248
(0.0241 to 0.0255)
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Table 6: Descriptive Statistics
Entire Cohort (n = 425228)

Osteoarthritis
Diabetes
Hypertension
Depression
Smoking
Female Sex
Alcohol
Stress
Epilepsy
Schizophrenia
Anxiety
Cancer
CVD
COPD
Rheumatoid Arthritis
Lipid Disorder
PCOS
CKD
TCA
Osteoporosis
Leg Injury
Family History of
Osteoarthritis
Family History of DM

n cases
41853
28979
66030
61977
17844
246866
6467
12636
2979
6379
30326
17653
23502
7265
3263
76253
1154
14767
13035
14384
12411
282
4578

%

Development Set (n = 265228)

9.8%
6.8%
15.5%
14.6%
63.9%
58.1%
1.5%
3.0%
0.7%
1.5%
7.1%
4.2%
5.5%
1.7%
0.8%
17.9%
0.5%
3.5%
3.1%
3.4%
2.9%

n cases
26013
18140
41185
38629
11037
153664
4038
7907
1842
3955
18894
11139
14730
4515
2039
47619
706
9283
8114
8971
7808

0.1%
1.1%

168
2851

%

Validation Set (n = 160000)

9.8%
6.8%
15.5%
14.6%
63.8%
57.9%
1.5%
3.0%
0.7%
1.5%
7.1%
4.2%
5.6%
1.7%
0.8%
18.0%
0.5%
3.5%
3.1%
3.4%
2.9%

n cases
15840
10839
24845
23348
6807
93202
2429
4729
1137
2424
11432
6514
8772
2750
1224
28634
448
5484
4921
5413
4603

0.1%
1.1%

114
1727

%
9.9%
6.8%
15.5%
14.6%
64.2%
58.3%
1.5%
3.0%
0.7%
1.5%
7.1%
4.1%
5.5%
1.7%
0.8%
17.9%
0.5%
3.4%
3.1%
3.4%
2.9%

National
Prevalence
13.0%𝑎
8.7%𝑏
17.6%𝑐
11.3%𝑑
13.7%𝑒
50.4% 𝑓
2.4%𝑔
22.9%ℎ
0.4%𝑖
1.0%𝑗
> 12%𝑘
7.1%𝑙
5.4%ℎ
8.7%𝑚
0.9%𝑛
17.3%𝑜
6.5%𝑝
3.1%𝑞
10.0%𝑟 (40+)

0.1%
1.1%
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Entire Cohort (n = 425228)
n cases
Family History of
Hypertension
Lives in a rural location
Morbidity
-1 disease*
Multimorbidity
-2 disease*
-3 disease*
Age
-18 to 24
-25 to 44
-45 to 64
-65 and older
BMI
-Underweight (< 18.5
kg/m2 )
-Normal (18.5 to 24.9
kg/m2 )
-Overweight (25 to
29.9 kg/m2 )
-Obese (> 30 kg/m2 )
Personal Income
-Less than $30000
-$30000 to $49999
-$50000 to $74999
-Greater than $75000

%

Development Set (n = 265228)
n cases

%

Validation Set (n = 160000)
n cases

National
Prevalence

%

2904
88898

0.7%
20.9%

1817
55527

0.7%
20.9%

1087
33371

0.7%
20.9%

19.0%𝑠

127781

30.0%

79671

30.0%

48110

30.1%

38.4%𝑡

37679
10063

8.9%
2.4%

23565
6286

8.9%
2.4%

14114
3777

8.8%
2.4%

14.5%𝑢
4.9%𝑢

58947
143660
152924
69438

13.9%
33.8%
36.0%
16.3%

36962
89608
95161
43330

13.9%
33.8%
35.9%
16.3%

21985
54052
57763
26108

13.7%
33.8%
36.1%
16.3%

12.0%𝑣
34.5%𝑣
35.8%𝑣
17.7%𝑣

2694

1.9%

1680

1.9%

1014

1.9%

48920

34.0%

30541

34.1%

18379

33.9%

32%𝑤

49380
42834

34.3%
29.8%

30736
26639

34.3%
29.7%

18644
16195

34.4%
29.9%

40%𝑤
27%𝑤

2243
297791
102784
7

0.6%
73.9%
25.5%
0.0%

1401
185981
64016
6

0.6%
74.0%
25.5%
0.0%

842
111810
38768
**

0.6%
73.8%
25.6%
0.0%
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𝑎

Canadian Chronic Disease Surveillance System (CCDSS) 2013/14(28)
Canadian Chronic Disease Surveillance System (CCDSS) 2008(208)
𝑐
Canadian Community Health Survey (CCHS) 2011 (209)
𝑑
Canadian Community Health Survey (CCHS) 2012 (210)
𝑒
Canadian Tobacco Use Monitoring Survey (CTUMS) 2012 (208)
𝑓
Statistics Canada (211)
𝑔
National Population Health Survey (NPHS) 2006 (212)
ℎ
Canadian Community Health Survey (CCHS) 2009/10 (208)
𝑖
Canadian Community Health Survey (CCHS) 2010/11 (213)
𝑗
Public Health Agency of Canada (214)
𝑘
Offord et al (215)
𝑙
Canadian Community Health Survey (CCHS) 2015 (29)
𝑚
Canadian Chronic Disease Surveillance System (CCDSS) 2008 (208)
𝑛
Ontario Rheumatoid Arthritis administrative Database (ORAD) (216)
𝑜
Canadian Health Measures Survey (CHMS) 2009/10 (208)
𝑝
Lujan et al. (217)
𝑞
Canadian Health Measures Survey (CHMS) 2007/08 (218)
𝑟
2009 Canadian Community Health Survey – Osteoporosis Rapid Response (219)
𝑠
Statistics Canada (220)
𝑡
Canadian Community Health Survey (CCHS) 2014 (29)
𝑢
Canadian Community Health Survey 2011/12 (208)
𝑣
Canadian Census 2012 (221)
𝑤
Canadian Health Measures Survey (CHMS) 2009/10 (222)
*Morbidity and multimorbidity considered the following diseases: asthma, arthritis, COPD, diabetes, cardiovascular disease, mental
disorder (mood disorder and/or anxiety), Alzheimer's disease and related dementias, cancer, stroke.
**Cell counts of 5 or less have been suppressed.
𝑏
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4.2

Missing Data and Multiple Imputation

Table 7 displays the amount of missing data in fields where data were missing, such as age or
BMI. All other variables were assessed under the assumption that the absence of an indication of
risk factor presence signified that the risk factor was not present in the individual. However, in
some cases, when compared to national averages, this assumption seemed unreasonable. For
example, a diagnosis of polycystic ovarian syndrome (PCOS) was found in only 0.5% of women,
whereas the national average of PCOS among women was 6.5%. As this seemed implausible,
PCOS was not considered in any analyses. The same approach was used in removing alcohol
use. Information regarding family history of the diseases of interest was not readily available for
most patients as several networks did not collect this information; family history was removed
accordingly.
Table 7: Variables with Missing Data

Smoking
Sex
BMI
Age
Income

Entire Cohort (n =
Development Set (n =
Validation Set (n =
425228)
265228)
160000)
n missing
%
n missing
%
n missing
%
397319
93%
247918
93%
149401
93%
69
0.02%
44
0.02%
25
0.02%
281400
66%
175632
66%
105768
66%
259
0.061%
167
0.063%
92
0.058%
22403
5.27%
13824
5.21%
8579
5.36%

Multiple imputation was used to account for missing data in sex, BMI, age, and income. Five
iterations were used, creating five imputed datasets. Smoking was not considered in analyses
because there was not sufficient information available to reliably perform imputation.
Risk factors deemed sufficiently well-recorded in the database and thus included in the models
were:
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Table 8: Risk Factors Available Within CPCSSN Database
Osteoarthritis
Osteoporosis
Previous leg injury
Older age
Obesity
Female sex

4.3

Diabetes
Hypertension
Older age
Lipid disorders
Obesity
Male sex
Schizophrenia
Depression
Low socioeconomic status

Hypertension
Older age
Diabetes
Obesity
Kidney disease
Tricyclic antidepressant
(TCA) use

Univariate Results

As described in Objective 1, the following results describe the univariate multivariable logistic
regression models that were constructed for diabetes, hypertension, and osteoarthritis. First, the
estimated β coefficients and odds ratios (with 95% confidence intervals) are presented followed
by model validation measures such as the ROC curve, AUC, and calibration plot for each model.
Note that direct comparisons of the magnitude of the estimated β coefficients to determine their
relative impact on disease risk would be inappropriate as these parameters were constructed for
the purpose of prediction, rather than causal inference. However, the significance of each
estimate can be considered. Of greatest importance are the model validation measures, as these
provide insight into model performance.
Table 9: Diabetes Univariate Results

Hypertension
Age
Lipid
disorders
BMI
Sex
Schizophrenia
Depression
Income

Reference
Category/Units
No
Yes
(Years)
No
Yes
(kg/m2 )
Male
Female
No
Yes
No
Yes
($10000)

β estimate
Reference
0.30
0.04
Reference
1.69
0.07
Reference
-0.30
Reference
0.63
Reference
0.14
-0.89

95% CI
0.26 to 0.35
0.03 to 0.04
1.64 to 1.73
0.07 to 0.08
-0.34 to -0.26
0.51 to 0.75
0.08 to 0.20
-1.15 to -0.64

Odds Ratio
Reference
1.35
1.04
Reference
5.42
1.07
Reference
0.74
Reference
1.88
Reference
1.15
0.41

95% CI
1.30 to 1.42
1.03 to 1.04
5.16 to 5.87
1.07 to 1.08
0.71 to 0.77
1.67 to 2.12
1.08 to 1.22
0.32 to 0.53
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AUC = 0.85

Figure 4: ROC Curve for Diabetes

Figure 5: Calibration Plot for Diabetes
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All estimated β coefficients for the diabetes model were found to be significant, as expected
given the large sample size. The model discriminated very well, as indicated by its ROC curve
and AUC (0.8523; 0.8476 to 0.8570). It slightly overestimated risk in lower risk patients, while it
estimated higher risk patients quite well (only a very slight underestimation), as depicted in its
calibration plot.
Table 10: Hypertension Univariate Results
Diabetes
Age
BMI
Chronic
Kidney
Disease
Tricyclic
Antidepressant
Use

Reference
No
Yes
(Years)
(kg/m2 )
No
Yes

β estimate
Reference
0.18
0.07
0.06
Reference
0.80

No
Yes

Reference
0.55

95% CI

0.74 to 0.85

Odds Ratio
Reference
1.19
1.07
1.06
Reference
2.22

0.49 to 0.62

Reference
1.74

0.12 to 0.23
0.06 to 0.07
0.06 to 0.07

95% CI
1.13to 1.26
1.06 to 1.07
1.06 to 1.07
2.09 to 2.35
1.63 to 1.86
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AUC = 0.84

Figure 6: ROC Curve for Hypertension

Figure 7: Calibration Plot for Hypertension
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Again, all estimated β coefficients from the hypertension univariate model were found to be
significant. The model discrimination was high, as indicated by its ROC curve and AUC
(0.8391; 0.8353 to 0.8429). It slightly underestimated risk in lower risk patients, while it
overestimated risk in moderate and higher risk patients, as depicted in its calibration plot.
Table 11: Osteoarthritis Univariate Results
Reference
Age
(Years)
Sex
Male
Female
BMI
(kg/m2 )
Previous Leg No
Injury
Yes
Osteoporosis No
Yes

β estimate
0.06
Reference
0.22
0.04
Reference
1.60
Reference
0.90

95% CI
0.05 to 0.06
0.17 to 0.27
0.03 to 0.04
1.52 to 1.68
0.83 to 0.98

Odds Ratio
1.06
Reference
1.25
1.04
Reference
4.94
Reference
2.47

95% CI
1.05 to 1.06
1.19 to 1.31
1.04 to 1.05
4.57 to 5.35
2.29 to 2.66

AUC = 0.83

Figure 8: ROC Curve for Osteoarthritis
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Figure 9: Calibration Plot for Osteoarthritis
Similar to the previous models, the estimated β coefficients for the osteoarthritis model were
found to be significant. Model discrimination was high, as indicated by its ROC curve and AUC
(0.8394; 0.8342 to 0.8446). It slightly overestimated risk in most patients, with the risk of those
at moderate risk overestimated the most and slight underestimation at both extremes.

4.4

Dependence Analysis

To measure the unadjusted correlation between outcomes, the ϕ coefficient was computed for
each outcome pair using the cor.test function in R. All pairs showed positive correlation. As
shown in Table 12, diabetes and hypertension were the most correlated outcomes, followed
closely by hypertension and osteoarthritis. Diabetes and osteoarthritis were the least correlated.
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Table 12: ϕ Coefficients
Diabetes
Diabetes
Hypertension
Osteoarthritis

Hypertension

Osteoarthritis

1
0.2420
(0.2380 to 0.2460,
p < 0.0001)
0.0975
(0.0934 to 0.1016,
p < 0.0001)

1
0.2086
(0.2045 to 0.2127,
p < 0.0001)

1

Partial correlation was also computed for each outcome pair using the pcor function, which
adjusted for the effects of all risk factors for both outcomes. For example, the partial correlation
between diabetes and hypertension was adjusted for all risk factors associated with diabetes
and/or hypertension. Again, all pairs were positively correlated, though the magnitudes of
correlation were reduced. As seen in Table 12, partial correlation was highest between diabetes
and hypertension; then hypertension and osteoarthritis; and diabetes and osteoarthritis.
Table 13: Partial Correlation
Diabetes
Diabetes
Hypertension
Osteoarthritis

1
0.1323
(0.1281 to 0.1366,
p < 0.0001)
0.0377
(0.0336 to 0.0419,
p < 0.0001)

Hypertension

Osteoarthritis

1
0.1227
(0.1183 to 0.1270,
p < 0.0001)

1

For each outcome pair, a copula was constructed to describe the non-linear dependence between
outcomes while adjusting for covariates using the univariate multivariable logistic regression
models. The Frank copula (170) was selected for use, given its ability to model weak
dependence well. The Frank copula can be seen below:
1
(𝑒 −𝜃𝑢 − 1)(𝑒 −𝜃𝑣 − 1)
(𝑢,
𝐶𝜃 𝑣) = − ln (1 +
)
𝜃
𝑒 −𝜃 − 1
Following the construction of univariate models for each outcome, estimates of the copula
parameter θ were obtained for each disease pair. Results from the estimation of θ for each
outcome pair are displayed in Table 13. A positive θ estimate represents a positive dependence
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(i.e., diseases tend to either both occur or not occur), while a negative θ estimate represents a
negative dependence (i.e., patients tend to develop one disease or the other but not both). The
strength of the dependence can be inferred from the magnitude of the θ estimate.
Table 14: θ Estimates
Diabetes
Diabetes
Hypertension
Osteoarthritis

Hypertension

1.6766
(1.5657 to 1.7876,
p < 0.0001)
0.6830
(0.5256 to 0.8405
p < 0.0001)

Osteoarthritis

1.9490
(1.8224 to 2.0755,
p < 0.0001)

All disease pairs exhibited a significant positive dependence after adjusting for risk factors, as
demonstrated by their θ estimates greater than zero.
Based on these copula models, trivariate probabilities were estimated. The following are
simulated patients whose trivariate probabilities have been estimated. For comparison, trivariate
probabilities under the assumption of independence have been estimated. The ratio between
these is presented for comparison purposes. Ratios greater than one indicate a higher risk based
on the copula than when assuming independence.
Example patient 1: Fifty-nine-year-old male whose BMI is 29 kg/m2 , who has osteoporosis and
an income of roughly $40000.
Table 15: Trivariate Probabilities for Example Patient 1
P(Diabetes, Hypertension,
Osteoarthritis)
P(0,0,0)
P(0,0,1)
P(0,1,0)
P(1,0,0)
P(0,1,1)
P(1,0,1)
P(1,1,0)
P(1,1,1)

Based on copula
model
0.8221
0.0466
0.0907
0.0121
0.0212
0.0015
0.0049
0.0008

Based on independence
assumption
0.8132
0.0529
0.0991
0.0064
0.0238
0.0015
0.0029
0.0002

Ratio
1.01
0.88
0.92
1.88
0.89
0.97
1.69
4.25
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Example patient 2: Seventy-nine-year-old woman whose BMI is 34 kg/m2 with an income of
roughly $35000 and free of any other risk factors.
Table 16: Trivariate Probabilities for Example Patient 2
P(Diabetes, Hypertension,
Osteoarthritis)
P(0,0,0)
P(0,0,1)
P(0,1,0)
P(1,0,0)
P(0,1,1)
P(1,0,1)
P(1,1,0)
P(1,1,1)

Based on
copula model
0.6088
0.0481
0.2362
0.0466
0.0282
0.0026
0.0239
0.0055

Based on independence
assumption
0.5798
0.0665
0.2633
0.0302
0.0371
0.0043
0.0169
0.0019

Ratio
1.05
0.72
0.90
1.54
0.76
0.61
1.42
2.84
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Chapter 5

5

Discussion

This chapter describes the key findings from the development of a PPM for multiple diseases,
with further discussion and elaboration. The strengths, limitations, and implications of this work
are discussed as well.

5.1

Overview of Results

Univariate models were constructed for diabetes, hypertension, and osteoarthritis that can be
used to estimate a patient’s risk of future disease development. Each model was comprised of a
set of β estimates that describe the contribution of each risk factor. All models had good
predictive ability, as demonstrated by their AUCs and calibration plots. Diabetes was the best
predicted outcome, with the greatest AUC (0.85) and the best calibration plot. The hypertension
model had the next best performance, with an AUC of 0.84 and a good calibration plot. The
osteoarthritis model had the lowest performance of the predicted diseases, with an AUC of 0.83
and a calibration plot that slightly underestimated risk in low-risk patients and slightly
overestimated risk in high-risk patients.
Following the construction of univariate models for each disease, an analysis of dependence
between each disease was conducted. This began with an analysis of the unadjusted correlation
measured using the ϕ coefficient. Diabetes and hypertension were the most correlated (ϕ =
0.24), followed by hypertension and osteoarthritis (ϕ = 0.21), then diabetes and hypertension (ϕ
= 0.10).
Next, the correlation between diseases after adjusting for the effects of relevant risk factors
(partial correlation) was determined. An examination of the partial correlation between each
disease pair revealed lower correlation coefficients between outcomes. This was expected, as
some dependence was anticipated to be explained by risk factors. Interestingly, the correlation
between hypertension and osteoarthritis (ϕ = 0.12) became roughly the same as that of diabetes
and hypertension (ϕ = 0.13) after adjustment. The correlation between diabetes and osteoarthritis
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decreased almost to zero after adjustment (ϕ = 0.04), indicating that most of the observed
association between these two diseases could be explained by their risk factors.
Finally, construction of copula models produced θ coefficients that describe the dependence
between outcomes that existed after adjusting for relevant risk factors. The largest θ estimate was
observed between hypertension and osteoarthritis (θ = 1.95), indicating that the strongest
dependence exists between this pair after adjusting for all risk factors. Diabetes and hypertension
had the next largest θ estimate (1.68), followed by diabetes and osteoarthritis (θ = 0.68). As
observed in the trivariate probability charts, the probability of developing multiple diseases was
greater when based on the copula models than when assuming independence. For example, for
example patient 1, the probability of developing all three diseases within five years was roughly
four times greater under the copula model than when assuming independence (0.0008 vs 0.0002).
The smallest increase was observed in the estimated probability of developing both diabetes and
osteoarthritis, which aligns with the previous correlation analyses that found the least correlation
between these two diseases. These findings indicate that risk estimates made under the
assumption of independence underestimate the risk of disease co-occurrence.

5.2

Comparisons of Univariate Models with Existing Models

Several models have been constructed in other works to individually estimate risk of each of
diabetes, hypertension, and osteoarthritis. In the following, the models produced by this thesis
will be compared with these existing univariate models.

5.2.1

Diabetes

Several models are commonly used to estimate an individual's risk of diabetes development.
These include the American Diabetes Association Questionnaire (ADA) (223), hosted on the
American Diabetes Association website; the Canadian Diabetes Risk Questionnaire (CANRISK)
(224), hosted on the government of Canada website; the Leicester Risk Assessment (LRA) (225),
found on the Diabetes UK and the UK National Health Service websites; and Australian Type 2
Diabetes Risk Assessment Tool (AUSDRISK) (226), found on The Australian Department of
Health website. Compared to these tools, the model derived from the CPCSSN database includes
many similar risk factors, with the notable addition of several diseases as risk factors, such as
depression or schizophrenia. However, the model derived for this thesis did not include several
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lifestyle or environmental risk factors as these were not stored in the database. The CPCSSN
database relied on EMR data, which is limited by the nature of the data collected (only clinically
relevant data) when compared to data collected for purpose through questionnaires or physical
examinations. The model derived for this thesis was derived from a considerably larger cohort
than previous models. It performed with similar, if not superior, discrimination compared to
traditional models. A comparison of the model derived for this thesis and existing models for
estimating diabetes risk is displayed below.
Table 17: Comparison of Diabetes Univariate Model with Existing Models
Name of
tool/study

Source
population

CPCSSN
(2018)

eCANRISK
(2009) (224)

CPCSSN
primary care
records
NHANES
(National
Health and
Nutrition
Examination
Survey) 19992004
CANRISK
study

LRA (2010)
(225)

AUSDRISK
(2010) (226)

ADA (2009)
(223)

Sample size
(development
set)
265228

Data
collection
method
Electronic
medical
records
Interviews,
physical
examinations,
and laboratory
tests

Method of
analysis

Validity

Multivariable
logistic
regression
Multivariable
logistic
regression

Internal
validation:
AUC of 0.85
Internal
validation:
AUC of 0.83

4366

Questionnaire

Random
sample of UK

6390

Interviews,
physical
examinations,
and laboratory
tests

Multivariable
logistic
regression
Multivariable
logistic
regression

Australian
Diabetes,
Obesity, and
Lifestyle
Study

6060

Interviews and Multivariable
laboratory
logistic
tests
regression

Internal
validation:
AUC of 0.75
Internal
validation:
AUC of 0.69
External
validation:
AUC of 0.72
Internal
validation:
AUC of 0.783
External
validation:
AUC of 0.66

5258

Table 18: Risk Factors Included in Diabetes Risk Estimation
Risk factor

CPCSSN

ADA

CANRISK

LRA

AUSDRISK
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Risk factor
Age
Sex
Diabetes in
family
High blood
pressure
Blood pressure
medication
use/history
Lipid disorder
Schizophrenia
Depression
Physical
activity
Obesity (BMI)
Gestational
diabetes
Waist
measurement
Eats
vegetables and
fruits
High blood
glucose history
Ethnic
group/country
of birth
Level of
education
Income
Smoking

5.2.2

CPCSSN
X
X

ADA
X
X
X

CANRISK
X
X
X

LRA
X
X
X

X

X

X

X

X

X

AUSDRISK
X
X
X

X
X
X
X

X

X

X

X
X

X
X

X

X

X

X

X

X

X

X

X

X

X

X
X
X

Hypertension

When dealing hypertension and other cardiovascular diseases, focus is often placed on predicting
severe events such as heart attack or stroke (9) rather than hypertension. However, some
prognostic predictive models aimed at the estimation of hypertension risk exist; these include
models based on the Framingham Heart Study (227); Women's Health Study (228); and data
combined from the Atherosclerosis Risk in Communities and the Cardiovascular Health Study
(229). These models included a wide variety of risk factors. The model derived for this thesis
included the fewest risk factors, as it was not able to include several lifestyle or environmental
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risk factors. Despite this, it performed the best out of all models, as it had the greatest AUC.
Compared to the other models considered, the model derived for this thesis had considerably
more individuals in its development set. Again, a comparison of the model developed for this
thesis and existing models used to estimate risk of hypertension are presented below. The
following tables present a comparison of each of these models.
Table 19: Comparison of Hypertension Univariate Model with Existing Models
Name of
tool/study

Source
population

CPCSSN

CPCSSN
primary care
records
Population
based

Framingham
Heart Study
(2008) (227)

Sample size
(development
set)
265228
1717

Women's
Health Study
(2009) (228)

US female
health
professionals

9427

ARIC/CHS
(2010) (229)

Population
based

7683

Data
collection
method
Electronic
medical
records
Interviews,
physical
examinations,
and laboratory
tests
Interviews,
physical
examinations,
and laboratory
tests

Method of
analysis

Validity

Multivariable
logistic
regression
Multivariable
Weibull
regression

Internal
validation:
AUC of 0.84
Internal
validation:
AUC of 0.79

Multivariable
logistic
regression

Internal
validation:
AUC of 0.71

Interviews,
physical
examinations,
and laboratory
tests

Multivariable
logistic
regression

Internal
validation:
AUC of 0.75

ARIC: Atherosclerosis Risk in Communities Study
CHS: Cardiovascular Health Study
Table 20: Risk Factors Included in Hypertension Risk Estimation
Risk factor
Diabetes
Age
Sex
BMI
Chronic kidney
Disease
Tricyclic
antidepressant

CPCSSN
X
X
X
X

Framingham
Heart Study
X
X
X

Women's
Health Study
X
X

ARIC-CHS
X
X
X
X

X
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Risk factor

CPCSSN

Framingham
Heart Study

Women's
Health Study

ARIC-CHS

X

X

X

X

X

X

use
Systolic blood
pressure
Diastolic blood
pressure
Family history
of hypertension
Ethnicity
Total/HDL
cholesterol
Lipoprotein
High-sensitivity
C-reactive
protein
Total grains
Current smoker
Lack of exercise

5.2.3

X

X
X
X
X
X
X
X
X

Osteoarthritis

Several models for the estimation of osteoarthritis risk have been developed, including the Tool
for Osteoarthritis Risk Prediction (TOARP) (230); the Nottingham knee osteoarthritis risk
prediction models (231); and models derived from data from the Rotterdam Study-1 (232) and
the Multicenter Osteoarthritis Study (MOST) (233). While the model derived for this thesis is
not specific to the location of osteoarthritis (as the case definition for osteoarthritis did not
specify the affected joint), all other models were designed to predict exclusively knee
osteoarthritis. Similar to hypertension, osteoarthritis predictive models made use of a wide
variety of risk factors, including radiographic measures such as the Kellgren and Lawrence
score. The model developed for this thesis did not use any radiographic measures; in fact, it was
the simplest model while maintaining the best discrimination according to internal validation.
The model developed for this work was based on a considerably larger sample of patients aged
18 and older; it did not restrict its sample to an older population at high risk of osteoarthritis in
order to enable the estimation of risk among all adults. A thorough comparison of each of these
models is displayed below.
Table 21: Comparison of Osteoarthritis Univariate Model with Existing Models
Name of

Source

Sample size

Data

Method of

Validity
66

tool/study

population

CPCSSN

CPCSSN
primary care
records
Population
based cohort
(age 45-79)

Tool for
Osteoarthritis
Risk
Prediction
(TOARP)
(2018) (230)
Rotterdam
Study-1
(2014) (232)

(development
set)
265228
641

Population
based cohort
(age 55+)

2628

Multicenter
Osteoarthritis
Study
(MOST)
(2016) (233)

Population
based cohort
(age 50-79)

3026

Nottingham
knee
osteoarthritis
risk prediction
models (2011)
(231)

Population
based cohort
(age 40+)

424

collection
method
Electronic
medical
records
Interviews,
physical
examinations,
and laboratory
tests,
including MRI
Interviews,
physical
examinations,
and laboratory
tests,
including xray
Interviews,
physical
examinations,
and laboratory
tests,
including xray
Interviews,
physical
examinations,
and laboratory
tests,
including xray

analysis
Multivariable
logistic
regression
Multivariable
logistic
regression

Internal
validation:
AUC of 0.83
Internal
validation:
AUC of 0.72

Multivariable
logistic
regression

Internal
validation:
AUC of 0.79

Multivariable
logistic
regression

Internal
validation:
AUC of 0.78
External
validation:
AUC of 0.76

Multivariable
logistic
regression

Internal
validation:
AUC of 0.70
External
validation:
AUC of 0.6
and 0.79

Table 22: Risk Factors Included in Osteoarthritis Risk Estimation
Risk factor

CPCSSN

TOARP

Age
Sex
BMI
Previous leg
injury
Osteoporosis
KL grade

X
X
X
X

X
X
X
X

Rotterdam
Study-1
X
X
X

MOST

X

X

X

Nottingham
X
X
X
X

X
X
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Risk factor

CPCSSN

TOARP

Rotterdam
Study-1

Joint damage
X
T2 cartilage
X
relaxation time
Genetic risk
X
Knee pain
X
Education level
X
Smoking
X
Contralateral/m
ultiple joint
osteoarthritis
Average
WOMAC score
Depression
Knee
misalignment
Occupation
Family history
WOMAC: Western Ontario and McMaster Universities arthritis index
KL: Kellgren and Lawrence

MOST

Nottingham

X
X
X
X
X
X
X

5.3
Comparison of Dependence Analysis with Existing
Dependence Analyses
While no studies have examined the dependence between diabetes, hypertension, and
osteoarthritis together, several studies have looked at each pair of diseases. The findings of this
thesis will be compared to the finding of other studies below.

5.3.1

Diabetes and Hypertension

Epidemiological and pathophysiological evidence supports an association between diabetes and
hypertension beyond what would be expected due to shared risk factors (234). Evidence from
epidemiologic studies found an association between blood pressure and blood glucose; this has
been observed in both children (235) (where the effect of risk factors such as drugs and alcohol
are minimal) and adults (236). Higher blood glucose levels have been associated with an
increased risk of developing hypertension in the future. After an 18-year follow-up, a long-term
Finnish study of men without hypertension found higher rates of hypertension development
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among those who had higher blood glucose concentrations at the outset of the study, even after
adjusting for age, adiposity, alcohol consumption, and baseline blood pressure (237). Similarly,
increased blood pressure is associated with an increased risk of diabetes. A study of 10000 men
in Israel found systolic blood pressure to be significantly associated with the development of
type 2 diabetes after five years (238). Several pathophysiological mechanisms have been
proposed to explain the association between these two diseases; however, none of these
definitively explain the relationship (234).
These findings align with those of the current analysis, which found an association between
diabetes and hypertension that persisted after adjusting for relevant risk factors. Higher
probabilities of diabetes and hypertension co-occurrence were estimated using the copula model
compared to those estimated by assuming independence.

5.3.2

Diabetes and Osteoarthritis

A recent systematic review and meta-analysis found diabetes and osteoarthritis to be associated
(239). Examination of osteoarthritis risk among 32,137 people revealed an odds ratio of 1.46
(95% confidence interval: 1.08 to 1.96) comparing people with diabetes to those without. Several
studies retained a significant association after adjusting for obesity (240–242), a considerable
risk factor for both diseases. A similar association was found for the risk of diabetes among
people with hypertension. An odds ratio of 1.41 (95% confidence interval:1.21 to 1.65) was
observed for diabetes development, comparing those with osteoarthritis to those without across a
group of 1,040,175 people. Interestingly, the association between diabetes and osteoarthritis was
significant in studies including hand osteoarthritis only (243,244), which highlights the
metabolic and systemic nature of hand osteoarthritis. Similarly, several studies have observed the
impact of metabolic syndrome (which includes diabetes) on the risk of osteoarthritis. The
Japanese Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study found that
the development of diseases considered components of metabolic syndrome was associated with
an increased risk of knee osteoarthritis development and progression (245). In fact, the cooccurrence of obesity, diabetes, and hypertension (all of which are components of metabolic
disorder) was found to increase the odds of experiencing hand osteoarthritis by a factor of 2.3
(95% confidence interval 1.3 to 3.9) (246).
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In the current analysis, some dependence was observed between diabetes and osteoarthritis (ϕ =
0.10). However, much of this was likely due to the effect of risk factors, as the observed
dependence decreased after adjusting for relevant factors (ϕ = 0.04). Accordingly, diabetes and
osteoarthritis had the lowest θ estimate of the disease pairs that were examined, corresponding to
the least dependence. As suggested by the literature, an association may exist between diabetes
and hand osteoarthritis, specifically; however, diagnoses of osteoarthritis within CPCSSN were
not specific to the joint(s) affected, thus sub-analyses could not be performed.

5.3.3

Hypertension and Osteoarthritis

Research investigating the relationship between hypertension and osteoarthritis found an
association between the two diseases (247–250). A research group in Korea studied hypertension
and its impact on osteoarthritis and found that while hypertension was not significantly
associated with osteoarthritis generally (251), it was significantly associated with an increased
risk of knee osteoarthritis (OR: 1.26, 95% confidence interval: 1.08 to 1.48) (252). Hypertension
is a component of metabolic disease, which has been linked to the development of osteoarthritis
(245,246), similar to diabetes. One theory hypothesizes that subchondral ischemia (inadequate
blood flow to bone tissues) due to the vessel-narrowing effects of hypertension results in
degradation of the joint cartilage, resulting in osteoarthritis (253–255).
Results of this thesis revealed an association between hypertension and osteoarthritis as well.
Correlation assessed via the ϕ coefficient revealed a relationship that persisted after adjustment
for relevant factors. When using the copula to estimate the trivariate probabilities, the estimated
probability of the co-occurrence of hypertension and osteoarthritis was greater than the estimated
probability assuming independence.
This thesis clearly demonstrated that when making estimations about the risk of multiple
diseases, it is inappropriate to assume that each disease is independence of the other. Instead,
models must be used that are able to capture the dependence that exists between diseases and
express this when estimating risk.
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5.3.4

Multiple Disease Risk Estimation

There has been one PPM developed for multiple diseases. Wang et al. (256) developed a model
for both COPD and congestive heart failure (CHF) using the EMR data of roughly 8000 patients.
Risk factors used as predictors included musculoskeletal disorders, heart arrhythmias, diabetes,
tobacco use, and asthma. Rather than considering predictors individually, predictors were
grouped by selecting those that best predicted the outcome, resulting in three groups: predictors
for COPD and CHF, predictors of only COPD, and predictors of only CHF. The main objective
of this study was to identify a set of shared predictors in addition to the development of a model
that accurately predicts the development of each disease. Predictors such as osteoarthritis, back
disorders, and cardiac dysrhythmias were shared by CHF and COPD; predictors such as diabetes
mellitus, chronic ischemic heart disease, and acute ischemic heart disease were mainly associated
with CHF; and predictors such as asthma, kidney stones, and tobacco use disorder were mainly
associated with COPD. The resulting predictive model performed well, with an AUC of 0.72.
Similar to the model developed for this thesis, Wang et al. used EMR data to derive their
prognostic predictive model.

5.4

Limitations

This research has several limitations that should be considered.
The current analysis was limited by the availability of information within the EMR. Information
describing key risk factors was unavailable, such as behavioural or environmental factors, as this
information is not typically collected during a clinical encounter. For the univariate models, this
likely resulted in an underestimation in the risk of patients who possess the uncollected risk
factor. For the dependence analysis, this potentially resulted in some of the observed dependence
being due to a risk factor that was not collected in the EMR. As the risk factor was not collected,
it could not be adjusted for. Such a factor could act in either direction; a risk factor could
increase or decrease the dependence between the diseases, thus the true dependence could be less
than or greater than what was observed. However, the use of information available within the
EMR has several advantages. The primary care setting is considered an ideal site to deploy
models to estimate patients’ risk of chronic disease as patients are commonly seen by a PCP
prior to disease development. EMR data are readily available to base predictions on in primary
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care; that is, no additional information needs to be collected in order to support the use of a
predictive model in clinical practice. The model would operate in the background of an EMR,
assessing the risk of disease among patients and flagging those at increased risk. Additionally,
analyses based on EMR data are not limited by poor statistical power due to small sample sizes.
EMR databases often collect the records of thousands of patients, providing sufficient power to
make strong conclusions.
Caution must be taken when applying the results to other settings, as the data used are likely not
representative of the general population. However, as previously mentioned, primary care is an
excellent setting where predictive models can be used to identify high-risk patients by estimating
risk of chronic disease. Thus, deriving predictive models in the same setting that they will be
used is ideal.
There are several errors that may occur that would result in a diagnosis not being recorded by the
PCP, resulting in missing data. First, the PCP must correctly identify and diagnose the disease. It
is possible that a disease may go undetected or undiagnosed and would not be recorded in the
EMR. Second, the PCP must record the diagnosis in the EMR; diagnoses of certain diseases may
carry stigma, limiting the PCP's willingness to record the diagnosis in the EMR. For example, a
diagnosis of schizophrenia sometimes carries stigma; a PCP may want to be completely certain
of their diagnosis before recording it in the EMR and may not record the diagnosis otherwise.
Third, in CPCSSN, the diagnosis found in the Billing table corresponds to the diagnosis that is
most responsible for the visit, or the most responsible diagnosis. The PCP must be sufficiently
motivated to record any additional diagnoses in the Health Condition table. However, a thorough
chart review was used to validate the CPCSSN disease-case algorithms that resulted in high
sensitivity and specificity for these algorithms. Other conditions relied upon case definitions
created for the purpose of this thesis; these case definitions have not been validated. However, all
efforts to make these definitions as accurate as possible have been performed, including a review
of relevant literature; a comprehensive examination of the database; and review by an expert
EMR user who was a member of the research team (PCP).
There may have been some bias introduced through patterns in physician diagnosis of diabetes,
hypertension, and osteoarthritis. For example, should a physician diagnose a patient with
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diabetes, it is likely that they will assess for related conditions, such as hypertension. In some
cases, a diagnosis of hypertension would have gone undetected had the physician not diagnosed
the patient with diabetes. This may have led to some dependence between these diseases being
due to patterns in diagnosis.
No external validation was performed for the univariate multivariable models. This would have
required access to an external data source from a similar yet distinct population. Access to such a
database was unavailable. Accordingly, the univariate models can only be confidently applied to
the data from which they were derived. However, the univariate models were intended to be
specific to the Canadian primary care population and can be confidently applied to this setting.
The nested nature of the CPCSSN database results in clustered data, in which patients within the
same group are likely more similar than those in different groups; for example, patients who
receive care from the same PCP are more likely to be similar than those who receive care from a
different PCP. This typically requires a methodology capable of accounting for the clustered
nature of the data; however, linkages between patients and PCPs were unavailable, thus clustered
analyses were not performed.
The CPCSSN case definition used to identify patients with diabetes does not separate patients by
type of diabetes. As such, all diagnoses of diabetes were treated as type 2 diabetes. However,
these are different diseases with distinct etiologies, each with unique risk factors. Many external
factors contribute to risk of type 2 diabetes, such as obesity, diet, and smoking (257), whereas
type 1 diabetes has been linked to more genetic factors (258). This likely resulted in
misclassification bias. However, the amount of bias introduced was likely minimal, as type 1
diabetes makes up only 10% of all cases of diabetes, based on national statistics (259).
Additionally, type 1 diabetes is usually diagnosed in childhood. Given that only incident cases of
diabetes in adults (18 or above) are being considered, these cases are more likely to be type 2
where adult onset is more common. Similarly, diagnoses of osteoarthritis did not specify which
joint was affected. Thus, osteoarthritis included any diagnosis of osteoarthritis, irrespective of
location.
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5.5

Implications

Although constructed for the purpose of developing a combined prognostic predictive model for
diabetes, hypertension, and osteoarthritis, the univariate models developed for this thesis could
be used to independently estimate a patient's risk of each disease. External validation should be
performed prior to deployment; however, each model's strong internal validation in a Canadian
primary care population indicates that these models would perform well in a primary care setting
in Canada. For example, the univariate model for diabetes development could be used by PCPs
to estimate a patient’s risk of developing diabetes in the next 5 years. This model could either
operate in the background, flagging high-risk patients, or as requested by the PCP where they
desire a risk estimate. The PCP can then suggest interventions aimed at reducing the patient’s
risk of developing diabetes.
It is widely known that chronic diseases tend to co-occur or cluster within individuals. As
chronic diseases often have similar risk factors, it is sometimes assumed that this clustering is
due to their shared risk factors. However, this thesis found that chronic diseases tended to cooccur more frequently than can be explained by their risk factors. This could be a result of many
factors such as patient susceptibility or shared disease processes. Irrespective of the mechanism
resulting in this dependence, a thorough understanding of the dependence between diseases is
necessary to enable the construction of a prognostic predictive model for the development of
multiple chronic diseases. This work examined the dependence between diseases using a variety
of techniques including correlation, partial correlation, and copula modelling. Based on these
methods, this thesis confirms the findings of previous works that have also demonstrated
dependence between diabetes, hypertension, and osteoarthritis (234,239,247–250). However, this
thesis is the first to do so using a method that accounts for the non-Gaussian distribution of
diseases while simultaneously adjusting for relevant risk factors. Based on this dependence
analysis, trivariate probabilities can be estimated to inform patients and their PCPs about their
risk of diabetes, hypertension, and osteoarthritis, including the co-occurrence of these diseases.
The availability of a prognostic predictive model capable of estimating a patient's risk of
multiple diseases could impact a physician's clinical care in many ways. First, this tool may
reveal a risk of the development of multiple diseases that is greater than what would be expected
when estimating disease risk independently; this elevated risk due to the dependence between
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diseases would likely have gone undetected otherwise. Informed of this risk, physicians can
suggest preventative interventions accordingly. For example, a patient’s risk of developing
diabetes and hypertension within the same 5-year window could be estimated by multiplying
their risk of diabetes by their risk of hypertension. This method assumes that these outcomes are
independent; however, this assumption is invalid for diabetes and hypertension. Instead, the
copula model would produce a greater risk of developing these two diseases. The difference
between these risks could be the difference between the PCP making a recommendation for
preventative action or not. The most useful and effective way to convey this information must be
the subject of future work.

5.6

Future Directions

The completion of this work enables the construction of a prognostic predictive model for
diabetes, hypertension, and osteoarthritis. The current model assumes dependence between
diseases does not vary between individuals, as θ is fixed for all patients after adjusting for risk
factors. Further research is needed to allow θ to vary depending on the values of a patient’s risk
factors.
The model developed in this thesis would present risks that are adjusted for the dependence
between diseases. Future work must investigate how best to present these risks in a way that is
meaningful to both patients’ and their PCPs. This will require specific research into how people
interpret information about joint risk, as this is harder to interpret than a single disease risk. For
example, does knowledge of increased risk of both diabetes development and hypertension
development have a different effect compared to knowledge of increased risk of diabetes on its
own.
The model can be operationalized into a tool capable of running in the background of an EMR to
flag high-risk patients and/or deliver risk estimates for patients when called upon by the PCP.
Future research should assess the effectiveness of this tool, ideally through a randomized
controlled trial in which PCPs are randomly assigned to receive the tool for use in their clinical
practice. This trial would assess outcomes such as whether PCPs make different decisions when
given information about a patient’s risk; whether patients are more likely to adopt a preventative
change when this recommendation is supported by a risk estimate; whether patient risk is
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reduced after receiving a risk estimate; and whether patient outcomes are ultimately changed by
receiving risk estimates. In the primary prevention of multimorbidity, this thesis takes a first step
in developing a tool capable of delivering risk estimates to inform PCP decision-making.

5.7

Conclusion

Through the construction of univariate models for diabetes, hypertension, and osteoarthritis, and
an examination of the dependence between each of these diseases, this thesis developed a
prognostic predictive model for the occurrence, including the co-occurrence, of these diseases.
Univariate models were able to accurately estimate patient risk, as demonstrated by their
discrimination and calibration. A dependence analysis using copulas to capture the non-Gaussian
distribution of each disease revealed the correlations between each disease pair. This dependence
analysis enabled the estimation of the risk of developing any combination of the diseases
considered. The development and implementation of this model in clinical practice will enable
accurate risk estimation to inform interventions aimed at risk reduction.
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Appendices
Appendix A: Summary of Validation Results for CPCSSN Diseases (193)
Condition
Hypertension
Diabetes

Sensitivity %
(95% CI)
84.9
(82.6 to 87.1)
95.6

Specificity %
(95% CI)
93.5
(92.0 to 95.1)
97.1

PPV %
(95% CI)
92.9
(91.2 to 94.6)
87.0

NPV %
(95% CI)
86.0
(83.9 to 88.2)
99.1
103

(93.4 to 97.9)
(96.3 to 97.9)
(83.5 to 90.5)
(98.6 to 99.6)
Depression
81.1
94.8
79.6
95.2
(77.2 to 85.0)
(93.7 to 95.9)
(75.7 to 83.6)
(94.1 to 96.3)
COPD
82.1
97.3
72.1
98.4
(76.0 to 88.2)
(96.5 to 98.0)
(65.4 to 78.8)
(97.9 to 99.0)
Osteoarthritis
77.8
94.9
87.7
90.2
(74.5 to 81.1)
(93.8 to 96.1)
(84.9 to 90.5)
(88.7 to 91.8)
Dementia
96.8
98.1
72.8
99.8
(93.3 to 100.0)
(97.5 to 98.7)
(65.0 to 80.6)
(99.6 to 100.0)
Epilepsy
98.6
98.7
85.6
99.9
(96.6 to 100.0)
(98.2 to 99.2)
(80.2 to 91.1)
(99.7 to 100.0)
Parkinsonism
98.8
99.0
82.0
99.9
(96.4 to 100.0)
(98.6 to 99.5)
(74.5 to 89.5)
(99.8 to 100.0)
COPD: chronic obstructive pulmonary disease; NPV: negative predictive value; PPV: positive
predictive value
Appendix B: Risk Factor Case Definitions
Risk Factor
Alcohol

Table Name
Billing
Health Condition
Encounter Diagnosis
Health Condition

Encounter Diagnosis

Risk Factor

Epilepsy
Stress

Disease Case*
Billing
Health Condition
Encounter Diagnosis
Risk Factor

Value
ICD-9 Codes:
• 303: Alcohol dependence syndrome
• 305.0: Non-dependent alcohol abuse
Inclusion:
• “alcohol”
Exclusion:
• “fam”
• “no”
• “FAS”
Inclusion:
• “alcohol dependence”
• “alcohol abuse”
• “alcoholism”
Inclusion:
• “alcohol”
Exclusion:
• “no”
• “alcohol n”
• “alcohol -”
Epilepsy
ICD-9 Codes:
• 308: Acute reaction to stress
• 309: Adjustment reaction
Inclusion:
• “stress”
Exclusion:
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Schizophrenia

Billing
Health Condition
Encounter Diagnosis
Health Condition
Encounter Diagnosis

Medication

Anxiety

Billing
Health Condition
Encounter Diagnosis
Health Condition

Encounter Diagnosis
Cancer

Billing
Health Condition
Encounter Diagnosis

• “no”
ICD-9 Code:
• 295: Schizophrenic disorders
Inclusion:
• “schizo”
Exclusion:
• “fam”
Prescription of second-generation antipsychotics:
• Aripiprazole (Abilify)
• Asenapine (Saphris)
• Brexpiprazole (Rexulti)
• Cariprazine (Vraylar)
• Clozapine (Clozaril)
• Iloperidone (Fanapt)
• Lurasidone (Latuda)
• Olanzapine (Zyprexa)
• Paliperidone (Invega)
• Quetiapine (Seroquel)
• Risperidone (Risperdal)
• Ziprasidone (Geodon)
Prescription of first-generation anti-psychotics:
• Chlorpromazine
• Fluphenazine
• Haloperidol
• Perphenazine
ICD-9 Code:
• 300.0: anxiety related neurotic
disorders
Inclusion:
• “anxiety”
Exclusion:
• “fam”
Inclusion:
• “anxiety”
ICD-9 Codes:
• 140-149: malignant neoplasm of lip,
oral cavity, and pharynx
• 150-159: malignant neoplasm of
digestive organs and peritoneum
• 160-169: malignant neoplasm of
respiratory and intrathoracic organs
• 170-175: malignant neoplasm of bone,
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Health Condition

Medication

connective tissue, skin, and breast
• 176: Kaposi’s sarcoma
• 179-189: malignant neoplasm of
genitourinary organs
• 190-199: malignant neoplasm of other
and unspecified sites
• 200-208: malignant neoplasm of
lymphatic and hematopoietic tissue
• 209: neuroendocrine tumours
• 239: neoplasms of unspecified nature
Inclusion:
• “cancer”
• “neoplasm”
Exclusion:
• “fam”
Prescription of chemotherapy drugs:
• Mechlorethamine (nitrogen mustard,
Mustargen)
• Melphalan (Alkeran, L-PAM)
• Chlorambucil (Leukeran)
• Cyclophosphamide (Cytoxan,
Procytox)
• Ifosfamide (Ifex)
• Estramustine (Emcyt)
busulfan (Myleran, Busulfex)
• Dacarbazine (DTIC)
• Temozolomide (Temodal)
• Carmustine (BiCNU, BCNU)
• Lomustine (CeeNU, CCNU)
• Streptozocin (Zanosar)
• Cisplatin (Platinol AQ, Platinol)
• Carboplatin (Paraplatin, Paraplatin AQ)
• Oxaliplatin (Eloxatin)
• Thiotepa (ThioTEPA)
• Methotrexate
• Raltitrexed (Tomudex)
• Pemetrexed (Alimta)
• Cladribine (Leustatin)
• Fludarabine (Fludara)
• Mercaptopurine (Purinethol, 6-MP)
• Thioguanine (Lanvis, 6-TG)
• Azactidine (Vidaza)
• Capecitabine (Xeloda)
• Cytarabine (Cytosar, Ara-C)
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•

Cardiovascular
Disease

Billing
Health Condition
Encounter Diagnosis

Health Condition
Encounter Diagnosis

5-fluorouracil (Adrucil, 5-FU, Efudex
[topical])
• Gemcitabine (Gemzar)
• Bleomycin (Blenoxane)
• Dactinomycin (Cosmegen,
actinomycin-D)
• Daunorubicin (Cerubidine,
daunomycin)
• Doxorubicin (Adriamycin)
• Epirubicin (Pharmorubicin)
• Idarubicin (Idamycin)
• Mitomycin (Mutamycin)
• Mitoxantrone (Novantrone)
• Liposomal daunorubicin (DaunoXome)
• Liposomal doxorubicin (Myocet)
• Pegylated liposomal doxorubicin
(Caelyx)
• Asparaginase (Kidrolase)
• Docetaxel (Taxotere)
• Paclitaxel (Taxol)
• Vinblastine (Velbe)
• Vincristine (Oncovin)
• Vinorelbine (Navelbine)
• Vindesine (Eldesine)
• Irinotecan (Camptosar)
• Topotecan (Hycamtin)
• Etoposide (Vepesid, VP-16)
• Teniposide (Vumon, VM-26)
• Hydroxyurea (Hydrea)
• Octreotide (Sandostatin, Sandostatin
LAR)
• Mitotane (Lysodren)
• Procarbazine hydrochloride (Matulane)
• Arsenic trioxide
• Pofimer sodium (Photofrin)
• Altretamine (Hexalen, Hexastat)
ICD-9 Codes:
• 410-414: ischemic heart disease
• 415-417: diseases of pulmonary
circulation
• 420-429: other forms of heart disease
Inclusion:
• “cardiovascular disease”
• “CVD”
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Medication

Diabetes
COPD
Rheumatoid
Arthritis

Disease Case*
Disease Case*
Billing
Health Condition
Encounter Diagnosis
Health Condition
Encounter Diagnosis

Hypertension
Lipid Disorder

Disease Case*
Billing
Health Condition
Encounter Diagnosis
Health Condition

Lab
Medications

Bipolar Affective
Disorder

Billing
Health Condition
Encounter Diagnosis

• “coronary artery disease”
• “CAD”
• “heart attack”
• “myocardial infarction”
• “heart disease”
Exclusion:
• “fam”
Prescription of anticoagulant medications:
• Rivaroxaban (Xarelto)
• Dabigatran (Pradaxa)
• Apixaban (Eliquis)
• Heparin (various)
• Warfarin (Coumadin)
Prescription of antiplatelet agents:
• Clopidogrel (Plavix)
• Dipyridamole
• Prasugrel (Effient)
• Ticagrelor (Brilinta)
Diabetes
COPD
ICD-9 Code:
• 714: rheumatoid arthritis and other
inflammatory polyarthropathies
Inclusion:
• “rheumatoid arthritis”
Exclusion:
• “fam”
Hypertension
ICD-9 Code:
• 272: disorders of lipid metabolism
Inclusion:
• “lipid”
• “cholesterol”
Exclusion:
• “fam”
LDL measurement: 3.37-9 mmol/L
Inclusion:
• “statin”
Exclusion:
• “nystatin”
ICD-9:
• 296.4: bipolar affective disorder, manic
• 296.5: bipolar affective disorder,
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Health Condition
Encounter Diagnosis

Chronic Kidney
Disease

Billing
Health Condition
Encounter Diagnosis
Health Condition
Encounter Diagnosis

Lab

Tricyclic
Antidepressant
(TCA) use

Medication

Osteoporosis

Billing
Health Condition
Encounter Diagnosis
Health Condition
Encounter Diagnosis

depressed
• 296.6: bipolar affective disorder, mixed
• 296.7: bipolar affective disorder,
unspecified
Inclusion:
• “bipolar”
Exclusion:
• “fam”
ICD-9:
• 585: chronic renal failure
Inclusion:
• “chronic kidney disease”
• “CKD”
• “chronic renal failure”
Exclusion:
• “fam”
Occurrence of the following laboratory results:
• Estimated glomerular filtration rate
(eGFR) less than 60 mL/min/1.73 m2
(260)
• Serum creatinine greater than 120
mol/L for men or 90 mol/L for
women (261)
• Urine albumin/creatinine ratio greater
than 20 mg/mmol for men or 28
mg/mmol for women (84)
• Serum albumin greater than 300 mg/L
(260)
Prescription of:
• Amitriptyline
• Amoxapine
• Desipramine (Norpramin)
• Doxepin
• Imipramine (Tofranil)
• Nortriptyline (Pamelor)
• Protriptyline (Vivactil)
• Trimipramine (Surmontil)
ICD-9 Code:
• 733: Osteoporosis and other bone
disorders
Inclusion:
• “osteoporosis”
Exclusion:
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Medications

Leg Injury

Billing
Health Condition
Encounter Diagnosis

BMI

Exam

Family History of
Osteoarthritis

Family History

Family History of
Diabetes

Family History

Family History of
Hypertension

Family History

Family History of
Depression

Family History

Stroke

Billing
Health Condition
Encounter Diagnosis

Health Condition
Encounter Diagnosis

Asthma

Billing
Health Condition
Encounter Diagnosis

• “fam”
Prescription of:
• Alendronic acid
• Risedronic acid
• Ibandronic acid
ICD-9 Codes:
• 820-29: fracture of lower limb
• 843: sprain or strain of hip and thigh
• 844: sprain or strain of knee and leg
• 928: crushing injury to lower limb
Based on:
• BMI (kg/m2) as recorded in EMR
• Height (m) and weight (kg) as recorded
in the EMR on the same date
Inclusion:
• “osteoarthritis”
Exclusion:
• “no”
Inclusion:
• “diabet”
Exclusion:
• “no”
Inclusion:
• “hypertens”
Exclusion:
“no”
Inclusion:
• “depress”
Exclusion:
“no”
ICD-9 Codes:
• 430: Subarachnoid hemorrhage
• 431: Intracerebral hemorrhage
• 432: Other and unspecified intracranial
hemorrhage
• 434: Occlusion of cerebral arteries
Inclusion:
• “stroke”
Exclusion:
• “fam”
ICD-9 Code:
• 493: Asthma
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Health Condition
Encounter Diagnosis

Inclusion:
• “asthma”
Exclusion:
• “fam”

Curriculum Vitae
Name:

Jason Black

Post-secondary
Education and
Degrees:

Western University
London, Ontario, Canada
2012-2016 Bachelor of Medical Sciences

Honours and
Awards:

NSERC Undergraduate Student Research Award
2012

Related Work
Experience

Research Analyst
Western University
2017-2018
Teaching Assistant
111

Western University
2018
Research Assistant
Western University
2016
Publications:
Alexandria Ratzki-Leewing, Stewart Harris, Selam Mequanint, Natalie H. Au, Jason E. Black,
Sonja Reichert, Judith B. Brown, Bridget L. Ryan. Severe Hypoglycemia Rates Highest Among
Those with Suboptimal Reporting Behaviour: Results of the InHypo- DM Study. ADA, 2018.
Accepted. Abstract.
Alexandria Ratzki-Leewing, Stewart Harris, Selam Mequanint, Natalie H. Au, Jason E. Black,
Sonja Reichert, Judith B. Brown, Bridget L. Ryan. Real-world risk indicators of severe
hypoglycemia in TD: Results of the InHypo-DM Study. ADA, 2018. Accepted. Abstract.
Alexandria Ratzki-Leewing, Stewart Harris, Selam Mequanint, Sonja M. Reichert, Judith Belle
Brown, Jason E. Black, Bridget L. Ryan. The real-world crude incidence of hypo- glycemia in
adults with diabetes: Results of the InHypo-DM study, Canada. BMJ Open Diabetes Research
and Care, 2017 In Press.
Jason E. Black, Amanda L. Terry, Daniel J. Lizotte. FRAMR-EMR: Framework for Prognostic
Predictive Model Development Using Electronic Medical Record Data with a Case Study in
Osteoarthritis Risk. BMC Prognostic and Diagnostic Research, 2017. Under Revision.

112

